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Abstract 
 
Over the last 20 years endovascular aneurysm repair (EVAR) has advanced dramatically. Early 
devices incorporated infra-renal fixation (IR), and were prone to delayed mechanical failure. 
Later devices incorporated bare metal stents that deploy in the supra-renal aorta (SR), improving 
durability, but potentially affecting long term renal function. This is the subject of continued 
research. 
Cystatin C (CC) is a low molecular weight protein, which has demonstrated great sensitivity at 
detecting renal dysfunction, despite only modest decreases in glomerular filtration rate (GFR). 
To date it has not been used to evaluate mid to long term renal function following EVAR. 
Neutrophil gelatinase associated lipocalin (NGAL) is a member of the lipocalin family of 
proteins, and rises considerably following renal insult due to surgery or nephro-toxicity.  With 
increasing numbers of abdominal aortic aneurysm (AAA) repairs, it’s important to have a 
reliable indicator and predictor of potential renal dysfunction following surgery. 
Aims 
 To assess long term renal function following EVAR, in particular SR-EVAR (Study 1) 
 To assess mid to long term renal function following EVAR with Cystatin C (Study 2) 
 To evaluate the role of NGAL in the management of AAA’s (Study 3) 
Results 
Study 1 assessed 180 EVAR’s performed between 1996 and 2001. Patients were grouped 
according to proximal fixation level. Renal function was recorded annually by serum creatinine 
xiii 
 
(sCr μmol/L) and Cockroft-Gault derived creatinine clearance (CrC ml/min). Paired renal data 
was available for 130 patients (IR: 67; SR: 63) with a mean follow up of 40.5 (range 0-120) 
months.  7 years post EVAR there was no significant deterioration in renal function within either 
the IR or SR group, with median sCr and CrC values of 117μmol/L and 56 ml/min, and 138 
μmol/L and 41 ml/min respectively (all p=NS, Mann Whitney U-Test). 
Study 2 was a two limbed study of 34 patients recruited over 12 months from June 2006. Patients 
were grouped according to previous AAA repair, either open repair (OR, n=17) or endovascular 
(EVAR, n=17). Both groups were analogous demographically. At 4 years follow up there was no 
significant deterioration in renal function within either the EVAR or OR group, with mean sCr, 
CrC and CC values of 112.75 μmol/L, 55.4 ml/min, 1.06 mg/L, and 112.94 μmol/L, 55.5 ml/min 
and 1.12 mg/L respectively (all p=NS, Mann Whitney U-Test). 
Study 3 was a prospective two limbed study of 44 patients recruited over 12 months from June 
2006 and grouped according to AAA repair, either open (OR, n=21) or endovascular (EVAR, 
n=23). Both groups were analogous demographically. There was a weak but statistically 
significant correlation between sCr (μmol/L) and NGAL (ng/ml) in the AAA population, with a 
Pearson correlation co-efficient of +0.24 (p<0.05). At both 4 and 24 hours post surgery the OR 
group had a statistically significantly higher median NGAL level than the EVAR group, 187.5 
ng/ml and 140.0 ng/ml vs. 182.0 ng/ml and 137.0 ng/ml respectively (all p<0.05, Mann Whitney 
U-Test). In proven renal dysfunction, NGAL was elevated above the diagnostic cut-off level at 4 
hours post procedure, although numbers were too small for statistical significance. 
 
 
xiv 
 
Conclusions 
Long term renal function remains unaffected following EVAR, irrespective of proximal fixation 
type, or biochemical marker of analysis.  
Although correlating with renal function in the AAA population, the role of NGAL in predicting 
potential renal dysfunction in these patients remains unclear, and warrants further research. 
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Chapter 1. The Abdominal aortic aneurysm (AAA) 
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1.1 The history of the abdominal aortic aneurysm repair 
Simply defined as a ‘hemispherical tumour of the vessel, which expands beneath the fingers with 
each pulsation’, the first documentation of arterial aneurysmal disease is from ancient Egypt (est. 
1552 B.C.), in some of the earliest known medical texts
1
.  
It would however take a further 3000 years for the abdominal aortic aneurysm (AAA) to be 
defined as a distinct entity, by anatomist Andreas Vesalius (1514-1564), who simply described ‘a 
pulsating tumour below the stomach’ in a selection of his patients2. Although recognised as a 
pathological feature, which could lead to death, it was not until the early 19
th
 century that 
surgical AAA management was contemplated.  
In 1817 pioneering work by Astley Cooper (1768-1841) lead to the first reported case of 
abdominal aortic ligation for the treatment of a leaking common iliac artery (CIA) aneurysm
3
. 
Despite initial surgical success, the patient succumbed on the second post-operative day.  
It would take a further hundred years for the first successful AAA repair. In 1925 Rudolph Matas 
(1860-1957) successfully ligated a syphilitic AAA in a 28 year old woman, with no apparent 
aneurysm associated complications
4. Whilst successful, the viability of the patient’s extremities 
was dependent on collateral blood flow, and could not be guaranteed long term. An alternative 
approach allowing maintenance of normal vascular anatomy was needed.  
The great leap in aneurysm surgery came from pioneering surgeon Alexis Carrel (1873-1948). In 
1912 he was awarded the Nobel Prize for demonstrating that sections of animal aortas could be 
successfully replaced by interposition grafts consisting of both arterial and venous homografts
5
. 
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This meant simply that aortic blood flow could be restored through the aorta to the lower limbs 
following surgery, with continuity of normal arterial anatomy.  
It would still take several decades before the first successful account of AAA repair in a human 
with a vascular homograft. In 1952 French surgeon Charles DuBost (1914-1991)
6
 described the 
repair of a large infra-renal aorto-iliac aneurysm by aneurysm resection, and restoration of 
vascular continuity by placement of an interposition graft, constructed from a previously 
harvested section of cadaveric thoracic aorta. The graft was successfully anastomosed from the 
infra-renal aorta onto the right common iliac artery, with vascular continuity to the left limb 
maintained by an end-to-side anastomosis of the left common iliac artery to the graft. With no 
reported complications, the patient made a full recovery.  
Despite these initial successes, the availability and size constrains of vascular homografts 
precluded their widespread use. The modern revolution in AAA repair occurred later in 1952, 
heralded by Vorhees et al.
7
, who successfully demonstrated the use of fabric conduits in lieu of 
homografts.  
With AAA repair progressing rapidly, refinement of technique was required to improve 
outcomes. The currently employed technique of open AAA repair by aneurysmorrhaphy and 
intra-luminal fabric graft reconstruction was popularised by Oscar Creech (1916-1967) in 1966 
8
. 
He advised against resection of the aneurysmal aorta, citing the high risk of concomitant damage 
to adjacent structures, and instead recommended opening the aneurysm sac, and anastomosis of 
the interposition graft from within, to the preserved native vessel both proximally and distally. 
This technique of open aneurysm repair was to gain worldwide acceptance as the standard 
treatment for AAA’s for the next few decades.  
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1.2 The Epidemiology of AAA’s 
It is currently estimated from both population and post-mortem studies that the prevalence of 
AAA’s within England is as high as 13%, with up to 5% of the population over the age of 60 
years harbouring an asymptomatic AAA. Within the English population the incidence of AAA’s 
increase sharply following the age of 50 years, finally reaching a peak at 80 years.  
With such a high prevalence, it is not surprising that the development of AAA’s in the infra-renal 
aorta is linked to common pre-disposing risk factors. These include increasing age, male sex, 
ethnicity, smoking, hypercholesterolaemia, hypertension, family history and pre-existing 
vascular disease
9, 10
. Of these risk factors, both smoking and being male are the most important, 
and increase the risk of AAA development approximately five fold. Additionally, having a first 
degree relative with an AAA doubles the risk of aneurysm development
11
.  
Although a controversial topic, the general consensus is to screen radiologically for AAA’s those 
patients who are male, over the age of 50 years, have affected relatives, and significant risk 
factors. 
 
1.3 The Natural History and Clinical features of AAA’s 
The natural history of the AAA is to expand and increase in size over time, leading to eventual 
risk of rupture. The best predictor of rupture is the antero-posterior (AP) size measurement of 
AAA’s, with a greater size leading to greater risk. Following a meta-analysis of 13 studies Law 
et al. confirmed this, with annual risk of AAA rupture ranging from 0% for less than 3 cm, to 
3.3% for 5-5.9 cm, and up to 24% for 7-7.9 cm
12
.  
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Most surgeons subsequently agreed that as long as the risk of surgery for AAA repair was less 
than the annual risk of rupture, then patients should undergo surgical treatment. 
The UK Small Aneurysm Trial
13
 aimed to clarify these issues and guide surgeons on whether 
small aneurysms (<5.5 cm) should be kept under radiological surveillance, or offered treatment, 
based on the risk of rupture and surgical risk. The trial found no survival benefit from operating 
on these small aneurysms (<5.5 cm), and recommended that AAA’s should be repaired 
surgically when the AP size exceeds 5.5 cm, or if symptoms relating to the aneurysm develop. 
Below 5.5 cm, all AAA’s should be kept under regular radiological surveillance. These 
conclusions were based on the findings that at or above 5.5 cm in size, the annual risk of AAA 
rupture outweighed the risk of open surgical AAA repair.  The only exception to this 
recommendation was for those AAA’s with a rapid expansion rate, which was felt to represent 
unpredictable aneurysm pathology, and an increased likelihood of rupture. It is generally 
recommended that if the annual AAA expansion rate is greater than 1 cm, then repair should 
occur regardless of the AAA size. 
One of the difficulties in AAA detection is that most are entirely asymptomatic, and are usually 
discovered incidentally when performing abdominal examination, or radiological imaging 
(Ultrasound/Computed Tomography) in search of other pathology. The presence of symptoms 
usually suggests AAA related complications such as fistulation (to bowel or vena cava), 
inflammation, infection, embolisation (to distal extremities or viscera), pressure related local 
effects, or imminent rupture. Any patient, presenting with sudden onset central abdominal and 
back pain, or unexplained collapse over the age of 50 years old, with or without a diagnosis of 
AAA, should be considered an AAA rupture, and treated as such until proven otherwise. Other 
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AAA related presentations, such as acute thrombosis or distal embolisation (causing peripheral 
ischaemia), or fistulation with the vena cava or duodenum (resulting in large gastrointestinal 
bleeding or high output cardiac failure), are rarer. 
 
1.4 The Typical Open surgical repair of an AAA 
The open surgical repair of an AAA as performed in most vascular centres follows a typical 
sequence of events, each of which may be changed or altered at local discretion.   
Following decision to treat an AAA, all patients give informed consent for the procedure. This 
highlights the main risks and complications, of open abdominal aortic surgery. These include 
both general and aneurysm specific complications, such as pneumonia, urinary sepsis, graft 
sepsis, haemorrhage, myocardial infarction, stroke, distal embolisation and limb loss, ‘trash feet’, 
need for further procedures, and death (which occurs in up to 5% of cases). 
All open AAA repairs are performed under general anaesthetic, with invasive monitoring of the 
patient in the form of urinary catheterisation, arterial and venous cannulation and possibly an 
oesophageal Doppler to assess cardiac output. An epidural may be used to reduce postoperative 
pain, and broad spectrum antibiotics are given at induction, and during the procedure as 
necessary to minimise the risk of graft infection.  
A trans-abdominal or retroperitoneal approach is used to access the aorta, with the 
retroperitoneal approach favoured in patients with severe adhesions following previous 
abdominal surgery, or other factors precluding an anterior abdominal approach (presence of 
stomas).  Trans-abdominal is the preferred abdominal approach, and is achieved either via mid-
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line incision or transverse abdominal incision, depending on surgeon preference, and whether 
there is any aneurysmal involvement of the iliac vessels.  
Following abdominal access, the small bowel is usually retracted and held either within or 
outside the abdominal cavity, to allow exposure of the retro-peritoneum. The peritoneum is then 
incised at the base of the small bowel mesentery, extending to the aortic bifurcation, allowing 
exposure of the aorta. 
The aortic neck and iliac vessel can then be dissected free to allow the application of clamps, 
once intravenous heparin (up to 5000 units) has been given. The proximal clamp is typically 
applied as close to the renal arteries as possible, so as to minimise the amount of residual native 
infra-renal aorta following repair, and subsequent aneurysmal formation. 
The anterior surface of the aneurysm sac can then be incised and any patent lumbar or gonadal 
vessels over sewn to arrest bleeding. The inferior mesenteric artery (IMA) is usually sacrificed, 
but can re-implanted later in the operation if there are concerns regarding the remaining colonic 
blood supply. 
The surgeon can now decide on the type of graft to be used (straight tube graft or bifurcated), 
and the size. The graft is then typically secured proximally with 2-0 or 3-0 mono-filament non 
absorbable sutures, with small pledgets constructed from excess graft to reinforce any areas of 
friable aortic wall. The proximal anastomosis is then tested, by allowing blood flow through the 
anastomosis into the graft, which has a separate clamp applied just distal to the anastomosis.  
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If an adequate seal is achieved, the distal anastomosis is performed to either aorta or iliac arteries 
depending on the graft used, and the graft flushed with heparinised saline prior to final closure to 
remove any air.  
The iliac vessel clamps are then released consecutively to avoid catastrophic falls in blood 
pressure. This occurs because of the rapid volume re-distribution into the large dilated distal 
ischaemic vascular beds, and the release into the circulation of accumulated vaso-active 
metabolites from the previously clamped limb.  
Assuming that haemostasis is achieved, and that the colon is viable (following IMA ligation), the 
aneurysm sac is loosely sutured over the graft to protect it from the small bowel, the small bowel 
is returned to the abdomen, and the abdominal incision closed.  
At the end of the procedure the lower limbs are assessed to ensure adequate perfusion, and the 
patient is transferred to either the intensive care unit (ITU) or high dependency unit (HDU) 
depending on pre-existing co-morbidities, and how they behaved physiologically during the 
procedure. Patients are then typically returned to the ward within 48 hours, and discharged from 
hospital between 7-10 days, depending on the presence of any complications. 
Whilst this general approach to AAA repair has and continues to serve patients well, the risks 
associated with major abdominal surgery and the high 30 day post-operative mortality of up to 
5%, have led many to seek less invasive or minimal access approaches to AAA repair. 
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2.1 Introduction 
For many years surgeons had sought to reduce the high risk of complications and mortality risk 
following major abdominal surgery for open AAA repair. With the elderly population on the 
increase in the United Kingdom and increasing numbers of AAA’s detected, the need for an 
alternative option to major abdominal surgery in those with AAA’s is becoming increasingly 
apparent.  
A minimally invasive approach for AAA repair is not a new concept. Intra-luminal wires, both 
with and without electrical current, had previously been employed to try and promote aortic 
thrombosis with limited success. Self expanding umbrella filters delivered via intra-luminal 
trochars had also been trialled, with similar high failure rates
14
. 
Exclusion of AAA’s by retrograde cannulation of the aorta and insertion of an endograft was 
initially performed on animal models. An artificial AAA was created in dogs by replacing an 
infra-renal segment of the aorta with a fusiform shaped Dacron® conduit. These artificial AAA’s 
were then excluded from the circulation via a trans-femoral introduction of an endograft, 
constructed from a knitted Dacron® graft overlapped by one third at both the proximal and distal 
ends, and sutured to a Palmaz® balloon expandable stent. The fabric covered stent essentially re-
lined the aorta, providing a new channel in anatomical continuity for the blood to flow
15
.  
The first endovascular repairs of abdominal aortic aneurysms (EVAR) in humans were reported 
in 1990 by Parodi et al.
15
 In a manner similar to previous studies, they created endografts from 
balloon expandable metal stents covered in Dacron® graft fabric (sutured to the stent at both 
ends). They demonstrated that friction from the radial force of the expandable metal stent against 
the aortic wall secured the graft to the aorta, maintained an adequate haemostatic seal, and 
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excluded the aneurysm from the circulation, allowing normal blood flow through the graft. The 
procedure involved femoral artery exposure and arteriotomy. The home-made endograft was 
then advanced through the femoral artery via an introducer sheath, under radiological guidance, 
to sit in the aneurysmal aorta. Once in position, a moulding balloon, already incorporated in the 
introducer sheath, was inflated (50% saline: 50% non-ionic contrast), and pulled distally through 
the endograft to deploy the proximal metal stent and secure the proximal endograft in the aorta.  
The distal stent was then expanded with a second incorporated balloon, securing the distal 
endograft in the aorta. A completion angiogram confirmed exclusion of the AAA from the 
circulation, and that there were no leaks around the endograft. Introducers and guide wires were 
then removed, and the femoral arteriotomy closed as per routine procedure. These home-made 
endografts were deployed successfully in five patients with large AAA’s, with no significant 
complications reported. The era of EVAR had now truly begun. 
Over the last 20 years, EVAR has rapidly evolved from the early home-made experimental 
endografts to commercially produced devices of the highest quality. They are available in tubular 
(aorto-aortic), aorto-uni-iliac (AUI) or bifurcated configurations. They may be one piece (uni-
piece), or modular (several components requiring construction during deployment), and attach to 
either the infra-renal (IR), or supra-renal (SR) abdominal aorta (via an uncovered portion of bare 
metal stent struts). More recent developments have been the creation of individually 
manufactured endografts with scallops at the leading edge of the graft, or fenestrations 
corresponding to the visceral arteries, for the treatment of juxta-renal aneurysms, or those with 
challenging aortic necks. The endograft fabric can consist of polyester (Dacron®) or 
polytetraflourotethylene (PTFE®), and may be either balloon or self expanding.  
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Endografts are used primarily to treat AAA’s, but are now also manufactured and designed 
specifically to treat a variety of thoracic diseases (aneurysm, dissection, traumatic transection, 
penetrating ulcers, pseudo aneurysms, aorto-bronchial fistulae and mycotic aneurysms)
16
.  
Whilst endograft technology has advanced significantly in the past 20 years, and EVAR has 
gained recognition and acceptance as an alternative to open AAA repair, there is still a great deal 
to learn. Concerns regarding long term endograft durability, higher financial costs of EVAR 
compared to open repair, and the need for continued post deployment surveillance persist 
today
17
. 
 
2.2 The Evolution of EVAR 
Tube grafts 
The first endografts constructed were a simple tube structure, with aorta to aorta attachment (see 
Figure 1). They were constructed from Dacron® grafts with a Palmaz® stent attached either 
proximally, or both proximally and distally. Commonly with this type of graft, an unfavourable 
distal aortic landing zone for the graft to attach resulted in frequent graft migration, and failure to 
maintain an adequate distal aortic haemostatic seal post deployment, resulting in continued 
aneurysm expansion and frequent aneurysm ruptures
18
. Failure to achieve this distal haemostatic 
seal on completion angiography commonly resulted in conversion of the EVAR to open AAA 
repair
19
. 
Several large studies of tube endografts seemed to confirm these findings. In 1998 May et al. 
reported their 5 year experience of EVAR using different configurations of endografts. They 
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found no significant difference in the peri-operative mortality between the different graft 
configurations, however Kaplan-Meier curves demonstrated a success probability of only 50% at 
40 months for tube grafts, compared to 80% for the others (aorto-iliac, bifurcated)
20
. In 2002 
Faries et al. report their experience of deploying 65 tube endografts from various manufacturers. 
They found no late aortic ruptures requiring surgery, but proximal attachment failure in 2 
patients, and distal site failure in 12, with an average time interval to failure of 12.9 months
21
. 
Due to universal reports of late complications, and because the proximity of the aortic 
bifurcation meant that only 5% of AAA’s were suitable for exclusion with tube-grafts19, they are 
no longer used and considered obsolete.  
 
 
 
Figure 1: Anatomical representation of an aortic tube graft 
14 
 
AUI grafts 
The next milestone in the development of endografts was the introduction of distal endograft 
fixation in a solitary common iliac artery. There was a general acceptance that common iliac 
fixation was needed to overcome the problems associated distally with tube grafts, in particular 
low levels of patients suitability and poor distal aorta quality. An AUI endograft involves a 
single tubular endograft, attached to both the infra-renal aorta proximally, and the most suitable 
iliac artery distally (absence of aneurysm, occlusion or tortuosity), referred to as the ipsilateral 
iliac. The contralateral common iliac is then occluded with an endovascular plug, and a femoral-
femoral crossover bypass performed (see Figure 2), to restore blood flow to the contralateral 
limb. Although this requires a formal surgical placement of a vascular graft, the associated risks 
seem to be low.  Walker et al. published their data on 136 patients following AUI stent-graft 
insertion, and found on median follow up of 7 months, only 2 graft infections and one graft 
thrombosis affecting the femoral-femoral graft
22
. 
Parodi et al. were one of the first centres to document the successful insertion of eight AUI grafts 
with encouraging early results
23
. Following the report of successful AUI deployment in 8 
patients, several other centres reported similar success rates with home-made endografts. Yusuf 
et al. reported the deployment of modified Gianturco® stent, Dacron® graft and Wallstent® 
(forming an AUI configuration) in 30 patients, with successful insertion in 25 (83.3%) of the 
patients and a 30 day overall operative mortality of 2 (6.6%)
24
. Thompson et al. demonstrated 
similar positive results with their tapered AUI graft constructed from an 8 mm thin-walled 
expanded PTFE® tube graft pre-dilated proximally to 35 mm, and tapered distally to 15 mm, 
with the graft sutured proximally to a 5 cm long pre-dilated Palmaz® stent. There was success in 
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52 (87%) of the 60 patients treated, with aneurysm exclusion in 49 (82%), and a peri-operative 
mortality of 3%
25, 26
. 
Larger scale studies using commercially manufactured AUI grafts confirmed all these positive 
findings. The EVT/Guidant trials
27
 compared AUI endografts with bifurcated grafts, tube grafts 
and open AAA repair. The primary end-points observed were operative morbidity and outcome 
at 1 year following EVAR. Endograft deployment was achieved in 94.2% of the AUI group, 
(comparable to the other endovascular techniques), and there was no significant difference in 
operative mortality between the groups (4.2% AUI, 2.6% bifurcated, 0% tube, 2.7% open repair). 
The incidence of Type 1 endoleak (proximal aortic seal) at one year were 2.4%, 2.3% and 3.8% 
for the AUI, bifurcated and tube groups respectively, and there were no reported late aneurysm 
ruptures or femoral-femoral graft thromboses. They concluded that the AUI endografts were as 
safe to use as the other configurations. 
Currently the most common indication for AUI endograft deployment is the presence of 
unilateral iliac artery occlusion, preventing aortic access via the blocked limb, and subsequent 
deployment of a contralateral limb. Due to their relatively rapid deployment, and exclusion of the 
aneurysm without having to deploy a contralateral limb, many currently advocate their use in the 
treatment of ruptured aneurysms.  
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Figure 2: Anatomical representation of an aortic AUI graft, with occluded contra-lateral limb, 
and femoral-femoral cross-over graft 
 
Bifurcated grafts 
Non-modular (Uni-piece) 
In current practice, the most commonly used endograft configuration is a bifurcated design. 
These endografts are an inverted Y shape, allowing proximal fixation in the infra-renal aorta, and 
distal fixation in each of the common iliac arteries, therefore maintaining anatomical normality, 
utilising the favourable common iliac arteries as a landing zone, and excluding any concomitant 
iliac artery aneurysms. 
The first documented use of bifurcated endografts was by Chuter et al. in 1994. The home-made 
devices were made from standard bifurcated Dacron® grafts with Gianturco® stents sutured at 
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both the proximal and distal extremities. Fifty two procedures were performed over a three year 
period, during which the device underwent modification, eventually resulting in its professional 
production (42 home made stent-grafts vs. 10 professionally made). Early results were 
promising, with 92% successful deployment of the home made devices, and 100% for the 
professionally made. However long term success was only 64% in the home made group and 
90% in the professionally made group. Device failures were attributed to graft thrombosis 
secondary to kinking and proximal graft migration
28, 29
. 
The first commercially available bifurcated device was manufactured by Endovascular 
technologies®, and consisted of an aortic main body, and two identical iliac limbs with self 
expanding stents attached to each of the landing zones
30
. The Endologix Powerlink® is currently 
the only commercially available uni-piece bifurcated endograft in production. The US 
multicentre trial for the Powerlink® stent-graft demonstrated this device to have a comparable 
outcome with respect to other EVAR devices, and less adverse post-operative events compared 
to open repair for AAA
31
. 
In general, uni-piece endografts have drawn criticism for the relative difficulty in deploying the 
contra-lateral limb, which frequently requires open surgical access, and the inflexibility of the 
devices due to equal dimensions of the limbs, precluding deployment in patients with different 
size or complex iliac systems. 
Modular design 
Modular endografts represent the pinnacle of bifurcated endograft design, and are currently the 
most commonly used and widely available endograft type. They are in essence a bifurcated 
endograft with one of the graft limbs detached from the main body of the graft. The principal 
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difference between other types of endograft is that the main aortic body has both long and short 
limbs distally. The main body is inserted via the most suitable iliac artery to attach to the aorta, 
as per other EVAR devices, and once deployed the long limb attaches to the iliac artery on the 
ipsilateral side. The short limb opens directly into the aneurysm sac, allowing catheterisation 
from the contralateral iliac artery, and deployment of the contralateral iliac limb, completing the 
bifurcated graft (see Figure 3). The endograft limbs can be pre-measured to sit correctly within 
the iliac arteries, or if necessary additional extensions can be placed at the end of deployment. 
The graft components are self expanding and held together by radial forces. Since different 
diameter and lengths of iliac limbs can be chosen, modular grafts are infinitely more adaptable 
than uni-piece endografts, and now form the mainstay of endografts used for EVAR.  
 
 
Figure 3: Anatomical representation of an aortic bifurcated graft 
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The first commercially produced modular endograft was the MinTec Stentor®. This was also the 
first endograft in which the graft fabric was supported along its entire length by the metal stent 
(not just at the proximal and distal landing sites), and eventually evolved into the Vanguard® 
endograft. Unfortunately these early modular devices were prone to late failure, with device 
migration, graft limb occlusions, stent kinking and limb dislocation all reported. In one of the 
first large studies to raise concerns regarding these early modular endografts, the Mount Sinai 
Medical Centre in the USA reported 60 out of 686 modular endograft deployments developed 
graft fatigue and failure. 43 of these were attributed to metallic stent fractures, and 14 to suture 
disruption, separating the graft fabric from the metal stent. The two modular endografts most 
commonly affected were the Vanguard® (16/60, with 9 body separations), and the Talent® 
endograft (24/60, with 23 metal stent fractures)
32
. Similar results and concerns were raised by 
other vascular centres. The Northern Vascular Centre, Newcastle, UK, reported similar results 
with their cohort of 55 Vanguard® endograft deployments. At median follow up of 40 months 
there were 3 device migrations, 12 occluded limbs and nine type 3 endoleaks. At 48 months, 
there was a survival rate of 67%, and an endoleak free survival of 81% 
33
.  
The Vanguard® and fellow early endograft Guidant Ancure/EVT® have subsequently been 
withdrawn due to these reported late failures, and ongoing concerns over their safety. Continuing 
development of endografts resulted in higher quality stents and design (particularly with respect 
to the type of proximal fixation), to reduce these worrying complications, and the current 
generation of modular endografts have excellent long term outcomes and durability. In a review 
of the EUROSTAR EVAR database in 2005, an analysis of the 6787 patients in the database 
found the Excluder®, Talent® and Zenith® (all modular endografts), were associated with a 
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lower risk of migration, kinking, occlusion, and need for secondary intervention compared to the 
Vanguard® and earlier modular endograft designs
34
.  
There are currently several commercially available EVAR devices in the UK forming a variety 
of configurations (see Table 1).  
Aortic endografts 
Device name (manufacturer) Device 
configuration 
Supra-renal 
component 
Powerlink/XL (Endologix) Unibody Optional 
Zenith Flex (Cook) Modular +/- 
fenestrated 
Yes 
Talent (Medtronic) Modular Yes 
Endurant (Medtronic) Modular Yes 
Anaconda (Vascutek/Terumo) Modular No 
Excluder (Gore) Modular No 
Aorfix (Lombard Medical) Modular No 
 
Table 1: Commercially available endografts in the UK (as of 2010) 
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2.3 Supra-renal (SR) versus infra-renal (IR) fixation 
Perhaps the most important development in endograft technology, came in response to these 
reports of early generation endograft late proximal attachment failure
35
, and subsequent graft 
migration
33
. These resulted in failure to exclude the AAA, and reports of delayed rupture 
following AAA repair.  The first generation endografts were deployed just below the renal 
arteries, and fixation was achieved via either radial forces or barbs or hooks in the endograft 
metal stent, so called infra-renal (IR) fixation. This IR portion of the aorta is susceptible to 
continued aneurysmal dilatation following endograft deployment
36
, which resulted in these 
proximal attachment failures. This resulted in several companies taking advantage of the disease 
free supra-renal (SR) aorta, and the development of endografts with an uncovered bare metal 
section of proximal stent which crosses the renal arteries, and attaches in the supra-renal aorta 
via a series of barbs or hooks (see Figure 4 & 5).  
 
 
Figure 4: Picture of uncovered trans-renal stent component of an endograft 
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Figure 5: A typical modular bifurcated aortic endograft with trans-renal placement 
Although associated with lower rates of proximal attachment failure
34
, concern was raised 
regarding bare metal wires crossing the renal arteries, disrupting blood flow, and affecting renal 
function.  
2.4 Renal function following SR EVAR 
The earliest studies assessing renal function following SR EVAR concentrated primarily on the 
direct disruption to blood flow in the renal arteries by the uncovered bare metal stents.  
England et al. demonstrated  peripheral or central renal ostia partial coverage in up to 40% of 
cases unilaterally, and 9% bilaterally
37
, raising concern that there could be significant disruption 
to renal blood flow, especially in those with bilateral coverage.  To assess this potential effect, 
Liffman et al. investigated four different stent wire configurations placed across an arterial 
orifice. Using complex experimental, numerical and analytical methods, they reported  on 
average only a 1% reduction in blood flow across a 3 mm targeted vessel, suggesting renal safety 
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in theory
38
. Similar work by Sun et al. using CT virtual intravascular endoscopy to assess the 
stent strut/ostia relationship, demonstrated no adverse renal complications, and preserved renal 
patency up to 8.3 months following SR endograft placement
39
. 
Direct assessment of biochemical renal function following SR EVAR was initially performed on 
animal (pig) models. Neither Whitbread et al.
40
 or Malina et al.
41
 could detect any biochemical 
renal dysfunction (using sCr as a renal marker), altered renal perfusion pressure, organ infarction 
or micro-embolisation, or radiological evidence of renal dysfunction up to 1 week following SR 
EVAR. 
The earliest assessment of renal function following SR EVAR in the human population was 
reported by Malina et al. in 1997. Using a homemade SR EVAR endograft in 18 patients, at 
median follow up of 6 months they found preservation of all renal arteries radiologically, and no 
elevation in the patients’ biochemical renal markers (sCr)42. The race to prove long term renal 
safety following SR EVAR had begun. 
Alsac et al. published their series of 277 patients (137 SR EVAR) with a mean follow up of 12.2 
months. Both groups showed a decrease in creatinine clearance post procedure (IR 10.9%; SR 
9.5%), but the difference between the groups was not statistically significant. They did however 
demonstrate that in patients with pre-existing renal impairment, the subsequent decrease in 
creatinine clearance was significantly greater in those patients treated with SR EVAR compared 
to IR
43
.  
As more Vascular centres offered EVAR, and patient numbers increased, longer follow up 
periods were reported. Alric et al. published their series of 315 (SR EVAR) patients with a mean 
follow up of 30.1 months. 17.2% of the supra-renal group suffered renal impairment (9.5% 
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persistent) vs. 16.4% for the infra-renal group (8.9% persistent), with no significant differences 
in dialysis requirements between the groups. Using multi-variate analysis they demonstrate that 
SR endografts were not significantly associated with renal impairment compared to IR
35
.  
Due to concern that most studies and series of patients reported were heterogeneous with respect 
to endograft type used, and the subsequent potential for bias, the Powerlink® Trial investigators 
report their series of 283 patients (91 SR EVAR) who underwent AAA treatment exclusively 
with the Endologix Powerlink® endograft during two US FDA trials between over a four year 
period. The endograft was available in both IR and SR variants. They found no significant 
difference between groups at any time period for creatinine clearance, renal impairment, renal 
events, or the need for dialysis, and concluded that SR EVAR was as safe as IR
44
 
Despite several positive reports, Bockler et al. published their experience with 663 patients (202 
SR EVAR) with a mean follow up of 37 months. They discovered an overall renal infarction rate 
of 11.9%, with 19% of SR EVAR causing varying degrees of renal infarction vs. 3.7% for the IR 
EVAR (statistically significant). Although a worrying finding, with concern once again re-
ignited over long term SR EVAR safety, they explain that this group comprised the more 
technically challenging patients, with adverse aneurysmal neck morphology, which could 
account for this discrepancy
45
. 
To date, using variable biochemical and radiological methods, several studies have demonstrated 
the apparent renal safety of SR EVAR in the mid to long term (see Table 2). However, as long 
term studies are now beginning to demonstrate late endograft failure following EVAR, there is 
still ongoing concern regarding the long term renal safety of SR EVAR, and continuing research 
is needed.  
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Investigators Year SR 
EVAR 
(n) 
IR 
EVAR 
(n) 
Mean 
F/U 
(months) 
Biochemical renal 
assessment used 
Malina et al. 
42
 1997 18 - 6 sCr 
Marin et al. 
46
 1998 37 - 10.3 sCr 
Kichikawa et al. 
47
 2000 18 - 14 sCr 
Lobato et al. 
48
 2000 35 - 11 sCr 
Izzedine at al. 
49
 2002 39 - 6 sCr, CrC 
Kramer et al. 
50
 2002 69 124 12 - 
Bove et al. 
51
 2003 37 - 29 sCr 
Alric et al. 
52
 2003 169 146 30 sCr 
Cayne et al. 
53
 2003 69 61 17 sCr, CrC 
Lau et al. 
54
 2003 32 57 12 sCr 
Surowiec et al. 
55
 2004 60 53 23 sCr 
Grego et al. 
56
 2004 47 - 16 sCr 
Mehta et al. 
57
 2004 111 385 19 sCr, CrC 
Alsac et al. 
43
 2005 137 140 12.2 sCr, CrC 
Parmer et al. 
44
 2006 91 192 30 sCr, CrC 
 
Table 2: Summary of renal studies post SR EVAR 
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2.5 Patient selection & eligibility for EVAR  
Studies have shown that up to 66% of patients with AAA’s may be anatomically suitable for 
EVAR
58
, and that this suitability depends on specific morphological characteristics of the 
aneurysm (see Table 3). These anatomical features include aneurysm neck length and degree of 
angulation, as well as the absence of thrombus in the aneurysm neck and conical shape. The size, 
tortuosity and aneurysmal status of the iliac vessels is also important, and all of the above must 
be considered when selecting patients for EVAR. 
The ideal length of AAA neck when considering treatment should be at least 15 mm, allowing 
sufficient non-aneurysmal proximal aorta to attain an adequate haemostatic seal with the 
endograft. Stanley et al. reported on their experience of deployment of the Zenith® endograft in 
238 patients, over a median follow up of 13.4 months, and found that endoleak rates (failure to 
maintain a proximal haemostatic seal), in necks less than or equal to 10mm was 57%, and that 
increased rates of proximal endoleak were significantly associated with both a neck contour 
change of 3 mm along the neck length, as well as a neck length of less than 20 mm. They 
concluded that neck contour, length and diameter are the most important factors in preventing 
endoleaks, and that 15 mm should be the minimum AAA neck length considered safe for 
EVAR
59
. Similarly, any AAA with a short or heavily calcified neck (a high percentage of aortic 
neck circumference calcified), are at an increased risk of proximal endoleaks, and EVAR should 
be used prudently
60
. 
AAA neck length is not the only consideration when planning patients for EVAR. The angle of 
the neck of the AAA with the non-aneurysmal aorta can also determine freedom from endoleaks. 
Sternbergh et al. report their series of 81 patients undergoing EVAR, and the consequences of 
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varying degrees of neck angulation. They demonstrated the risk of a patient experiencing one or 
more adverse post-operative events (death, conversion to open repair, and type 1 endoleak), as 
70%, 54.5% and 16.6% in patients with severe (> or = 60 degree), moderate (40-59 degrees), and 
mild (<40 degrees) angulation respectively. They recommend caution in patients with large AAA 
neck angulations, and recommend an angulation of less than 60 degrees for safe EVAR 
deployment
61
. For many years considered a restriction to EVAR, necessitating open AAA repair, 
newer technology endografts, in particular Aorfix® (Lombard Medical), have been specifically 
designed with flexible metal stent frames, allowing treatment  of the most complex AAA necks, 
with angulation approaching 90 degrees. 
In addition to AAA specific factors, the iliac vessels, through which the endograft must travel, 
must also be carefully assessed prior to EVAR. They should ideally be at least 7 mm in diameter 
to accommodate the large delivery catheters and sheaths of EVAR, and tortuosity as well as 
calcification, which account for up to 15% of patient exclusion from EVAR, should be 
minimal
62
. Whilst important in patient selection for EVAR, adverse iliac vessels are not an 
absolute contra-indication. The iliac vessels can be either pre-dilated or stented to overcome 
calibre constraints, and if necessary the use of a brachial to femoral artery guide wire, passed 
retrogradely from brachial to femoral artery and held under tension, can also aid delivery of the 
endograft. If all else fails, formal surgical access to the iliac vessels can be achieved to allow safe 
device delivery. 
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Selection criteria for endovascular repair 
 
Aortic endografts 
Aneurysm diameter > 55 mm or symptomatic 
 
Neck length  >  15 mm 
 
Neck angulation < 90 degrees 
 
Iliac vessels > 7 mm diameter 
 
Minimal tortuosity/calcification of iliacs 
 
 
Table 3: Eligibility criteria for EVAR (as of 2010) 
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2.6 A typical EVAR procedure 
The patient will have been formally assessed and consented in preparation for surgery as if for 
conventional open AAA repair. Suitable radiological imaging, usually in the form of a CT will 
be obtained pre-operatively to enable endograft sizing. The EVAR theatre should be capable of 
combined radiological and surgical procedures, and requires a C-arm for intra-operative 
radiological imaging.  
Once anaesthetised, the patient is prepped and draped, allowing access to both groins as well as 
the abdomen in case of conversion to open repair. A formal surgical dissection to the common 
femoral arteries is then performed, to allow the EVAR device catheters and sheaths to be 
advanced proximally into the AAA under radiological guidance. Once in position, the endograft 
is deployed. An additional intra-operative measure taken by this centre to minimize renal injury, 
(particularly infraction), and long term renal dysfunction is the angiographic imaging of the renal 
arteries following partial stent deployment. Whilst now commonplace, with renal artery marking 
on the fluoroscopy screen, this was not always traditionally performed. This allows confirmation 
of the correct device position prior to final deployment, and serves to reduce the incidence of 
partial or total renal artery occlusion. Following this, the ipsilateral and contralateral limbs are 
deployed, and balloon moulding is then performed to fully expand the device and ensure a tight 
haemostatic seal. The catheters and sheaths are then removed, and the arteriotomies closed in a 
routine fashion.  
As per open AAA repair, an inspection of the lower limbs is performed to exclude peripheral 
ischaemia.  
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2.7 Complications following EVAR 
As a minimally invasive procedure, EVAR avoids the stigmata associated with open AAA repair 
and major abdominal surgery, with suggested reduced rates of critical care support, myocardial 
and pulmonary insufficiency, and reduced recovery period. However, despite these positive 
attributes, EVAR has its own procedure specific range of potential complications, which have to 
be considered when planning EVAR.  
Endoleaks 
Defined simply as a ‘failure to exclude the aneurysm from the circulation’, endoleaks result in 
continued blood flow into the AAA sac, potential continued AAA sac enlargement, and delayed 
risk of AAA rupture (see Figure 6). Endoleaks are the most common procedure specific 
complication to occur following EVAR, and are broadly specified into 5 different types (see 
Table 4). Type 1 is the failure of the proximal or distal heamostatic seal, usually due to continued 
aneurysm neck dilatation or endograft migration distally. Type 2 is the result of patent aortic sac 
branches, usually lumbar arteries, but possibly sacral, gonadal or mesenteric arteries. Type 3 is 
due to endograft failure directly, with either a fracture in the metal stent structure, modular 
components disconnecting and separating from each other in vitro, or a tear in the endograft 
fabric. Type 4 is due to the fabric porosity of the endograft. Whilst continued aneurysm sac 
expansion typically means an endoleak is present, it can still occur in the absence of radiological 
confirmation. This is commonly referred to as endotension, or Type 5 endoleak, and is poorly 
understood. Although the aetiology is not clear, it has been theorised that direct pressure 
transmission by thrombus or the adjacent aortic lumen, un-detected low flow endoleak, and 
porosity of the stent-graft to serous fluid are to blame. 
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The endoleak rate following EVAR varies considerably between studies and depending on the 
type of endograft used. However in a systematic review of the published data on the safety and 
efficacy of EVAR conducted in 2005 (61 studies in total), comprising a total of 19804 EVAR 
patients, endoleak rates were reported as 6.8%, 10.3% and 4.2% for type 1, 2 and 3 respectively. 
They subsequently concluded that routine post EVAR radiological surveillance is necessary to 
detect these potentially significant complications
63
.  
 
 
Figure 6: The two most common types of endoleak. Type 1 is typically fixed at the time of 
surgery with an expandable aortic cuff stent. Type 2 usually resolve conservatively, but can be 
treated surgically or radiologically 
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Endoleak type Endoleak subtype Source of leak 
1 Proximal 
Distal 
Iliac Occluder 
 
Endograft attachment 
site 
2 Single vessel 
Multiple vessel (>2 
vessels) 
 
Collateral vessel (ie. 
lumbars) 
3 Junctional leak 
Suture hole 
Mid endograft hole 
 
Graft failure 
4 Endograft porosity Endograft wall 
5 Endotension Low flow endoleak 
Aortic lumen 
Thrombus 
Endograft porosity to 
serous fluid 
 
Table 4: Classification of endoleaks 
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Device migration and durability 
The primary aim of supra-renal endograft fixation is the reduction of device migration and 
subsequent haemostatic failure of the proximal seal zone by utilising the non-aneurysmal supra 
renal aorta. Several early studies demonstrated  a decreased incidence of device migration and 
proximal endoleak when comparing supra-renal with infra-renal deployed endografts, but were 
limited by their short follow up periods and relatively small patient numbers
46, 64
. The findings of 
these preliminary reports have subsequently been confirmed by several larger scale studies.  
The Zenith® Multicentre Trial
65
  was a large study reporting on 351 patients having undergone 
treatment with a supra-renal Cook Zenith® endograft, and followed  for up to 24 months. Risk of 
endograft migration >5mm at 12 months was 2.3%, (although this was higher when the 
endograft was oversized by >30%), and incidence of proximal type 1 endoleak at 12 and 24 
months were also acceptably low. However, despite promising results, with no infra-renal 
deployed endografts from the enrolled centres, for direct comparison with the Zenith® endograft, 
it was not possible to comment completely on the superiority of the supra-renal configuration. 
To overcome these drawbacks, Tonnessen et al. reported in 2005 their direct comparison of the 
mid to long term device migration rates between one make of infra-renal (Medtronic AneuRx®), 
and one make of supra-renal (Cook Zenith®) endograft, implanted in their centre over a seven 
year period. Minimum follow up was 12 months, with a mean follow up of 39 and 30.8 months 
for the infra-renal and supra-renal endografts respectively. Analysis demonstrated freedom from 
migration of 96.1%, 89.5%, 78.0% and 72.0% at 1, 2, 3 and 4 years respectively for the infra-
renal group, (85.7% of the patients with migration requiring further intervention). The 
corresponding values for the supra-renal group were 100%, 97.6%, 97.6% and 97.6%, at 1, 2, 3 
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and 4 years respectively. The difference between the migration rates was statistically significant, 
and highlighted the durability benefits of supra-renal fixation for endografts
66
.  
These studies highlighted that device migration is a time dependent phenomenon, with a reduced 
risk of endograft migration when using supra-renal fixation. Since there is risk of migration 
many years following deployment, it is currently necessary to monitor patients with radiological 
imaging annually, and indefinitely. 
Rarer EVAR complications 
Whilst the most common complications following EVAR are endoleaks and device migration, 
there are a host of recognised, but rare potential complications. As can occur with open 
aneurysm repair, any manipulation of the aneurysm sac carries a potential risk of distal micro-
embolisation affecting the lower limbs requiring embolectomy, or resulting in ‘trash foot’67, 68. 
Left colonic ischaemia has also been reported following embolisation of the inferior mesenteric 
artery
69
.  
Although rare, a case of peripherally seeded mycotic aneurysms following chronic endograft 
infection has been reported
70
.  
Insertion of large calibre catheters, guide wires, and the endograft delivery instruments have 
resulted in delivery vessel injury (rupture and dissection), and delayed pseudo-aneurysm 
formation has been reported.  
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2.8 Current status of EVAR (and future directions) 
The EVAR 1 trial
17, 71
 compared open vs. endovascular repair of AAA in a multi-centre 
randomised controlled trial. The end-points were mortality (aneurysm related and overall), 
durability, cost and health related quality of life (HRQL). In total 1082 patients were 
randomised. The 30 day mortality for EVAR was 1.7% vs. 4.7% for open repair, and although 
overall mortality between the groups was equivocal by 4 years, the aneurysm related mortality 
was still lower for EVAR (4% vs. 7%). The HRQL was equivocal between the two groups within 
6 months, although the cost for the EVAR group was significantly higher over the 4 years. This 
was predominantly due to the cost of the stent-grafts, and it is hoped that as endografts develop 
and EVAR gains greater acceptance, that costs reduce.  
Unfortunately the results were not as exciting for those patients deemed surgically unfit. The 
EVAR 2 trial
72
 compared EVAR vs. best medical treatment in those patients deemed unfit for 
open surgery. Ultimately following per-protocol analysis there was no benefit in favour of 
EVAR. 
A recent EVAR 1 trial update demonstrated at long term follow up, a continuing aneurysm 
related mortality advantage of 3% over open AAA repair, but no significant difference in all 
cause mortality or HRQL. Similarly, the EVAR 2 participants demonstrated no long term 
improved mortality. They concluded that with the higher costs of EVAR, and similar long term 
mortality to open AAA repair, that patient choice should dictate treatment method in the 
medically fit, and that greater consideration should be given to medical optimisation pre- 
procedure for the medically unfit
73
.  
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The results from the seminal EVAR Trials have helped cement EVAR as a viable and even 
preferable alternative to open surgical AAA repair.  
Fenestrated/branched stent-grafts (FEVAR) 
The most recent aortic endograft development comprises specially made endografts, with either 
scallops or fully covered integrated renal artery stents (see Figure 7), for the management of both 
short necked and juxta-renal AAA’s.  
 
Figure 7: A scalloped endograft on the left. An endograft with  a fully incorporated covered renal 
stent on the right. 
 
Whilst there are no randomized controlled trials to compare their use with open repair, there are 
promising early results from small series of patients in specialist centres.  
Anderson et al. from Australia, report on 13 patients from 1998-2000 with unsuitable infra renal 
necks. There was 100% deployment success, and no 30 day mortalities. Follow up ranged from 
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3-24 months, during which there was no endoleak and only one occlusion of a stented renal 
vessel
74
.  
Verhoeven et al. from the Netherlands, report on 18 patients with unsuitable aortic necks who are 
unfit for open surgery. Of the 46 targeted vessels (10 SMA, 36 renal arteries), 45 remained 
patent at the end of the procedure. One accessory renal artery was occluded by the stent-graft. 
There was one type 2 endoleak but no deaths. At mean follow up of 9.4 months, there were no 
additional renal complications, and all remaining targeted vessels remained patent
75
. 
The Cleveland Clinic in the USA have reported on 2 series of patients
76, 77
.  The first included 32 
patients (22 with short aortic necks and 10 with angulation or thrombus compromising neck 
quality). 83 visceral vessels were incorporated (most commonly renal arteries and SMA). All 
devices were successfully deployed. The only 30 day mortality was due to pneumonia, and 
endoleak rate at this time was 6.5%. There was one case of persistent type 2 endoleak, and 
continued aneurysmal sac growth. Mean follow up was 9.2 months, during which 6 patients had 
transient or permanent elevation of serum creatinine (one requiring haemodialysis), and of the 83 
vessels, three late stenoses (all successfully treated), and two renal occlusions were detected. The 
second series focused on renal function following fenestrated EVAR (FEVAR), and involved 72 
patients between 2001 and 2004 (23 patients with baseline renal insufficiency, and 49 patients 
without). 24 patients had deterioration in GFR >30% during the follow up period (mean 6 
months, range 1-24), and 17 patients experienced 19 renal events (10 renal artery stenoses, 5 
renal artery occlusions, and 4 patients required haemodialysis). Renal events and death were 
more common in the group with pre-operative renal dysfunction. They concluded that 
fenestrated endovascular repair is associated with a significant risk of adverse renal outcome 
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(16% in those patients with no pre-existing renal dysfunction, and 39% for those with pre-
existing renal dysfunction), and that patients must be followed closely (with renal duplex 
ultrasound and CT), particularly in the first month post procedure.  
In general the development of fenestrated and branched endografts has been slower than that of 
standard endografts for AAA’s. This is in part due to their relative rarity of juxta-renal 
aneurysms compared to AAA’s, and the greater complexities and costs involved in their 
manufacture. Recently Cook®, one of the major manufacturers of endografts have produced a 
fenestrated Zenith® endograft at a significantly reduced cost, making the routine endovascular 
treatment of juxta-renal aneurysms, or aneurysms with short necks, a viable and potentially cost 
effective option for the future. 
EVAR for ruptured AAA’s  
To date the use of EVAR for the treatment of AAA rupture has involved only small series of 
patients or individual case reports. The lack of data and seeming indifference to open surgical 
repair has led to considerable controversy in this subject. It has been suggested that only 20% to 
42% of AAA ruptures would be suitable for EVAR based on anatomical neck features
78
 
79
. 
Combined with the need for the patient to be haemodynamically stable to enable pre-procedure 
CT scanning, it is currently unclear as to how many patients would be eligible for EVAR. 
In a review of all the available literature on EVAR for ruptures, peri-operative mortality ranged 
from 9-45%, and of the 91 cases reported, there were 7 peri-operative endoleaks (two Type 1 and 
five Type 2), 15 incidents of renal failure, and hospital stay ranged from 2-70 days. The results 
were comparable to those for open repair
80
.  
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Peppelenbosch et al. report similar finding from their international multicentre study using the 
Talent AUI stent-graft. Of the 49 treated patients, operative blood loss, ICU admission times, and 
duration of mechanical ventilation were all statistically significantly shorter than for open repair. 
However, the 30 day mortality was 35% and 39% for EVAR and open repair respectively, and 
the 3 month all cause mortality was 40% and 42% respectively. There were no statistically 
significant differences in mortality between the operative methods
81
.  
Inconclusive results from studies like these have lead many to question the value of EVAR for 
AAA ruptures. 
There is still no consensus as to which stent-graft is best in EVAR for ruptures, but many 
advocate the use of AUI’s, as they only require cannulation of one iliac system to exclude the 
aneurysm, enabling completion with femoral-femoral crossover once haemodynamic stability is 
restored. The occasional difficulties in cannulation and attaching the short limb in modular stent-
grafts can lead to increased exposure to haemorrhage from rupture.  
The current logistical requirements of a dedicated endovascular suite with available and 
appropriately trained vascular surgeons, interventional radiologists, anaesthetists, CT personnel 
and theatre staff all acting in co-ordination, has so far meant that EVAR for ruptured AAA’s has 
been confined to specialist vascular centres. 
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Chapter 3. The assessment of renal function 
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3.1 Glomerular filtration rate and the clearance concept 
The excretion of soluble waste products by the kidney is achieved by glomerular filtration. In 
reality few metabolites and exogenous compounds are secreted by the renal tubules, and 
regulation of the fluid composition in the body is achieved almost entirely by variations in the 
tubular absorption or secretion of individual components. 
Renal insufficiency is defined simply as a reduction in the glomerular filtration rate (GFR). 
Therefore in order to assess renal function it is important to have an accurate, reproducible and 
reliable measure of the GFR. This is achieved in principal using the clearance concept
82
. This 
states that if a substance is freely filtered at the glomerulus and is not re-absorbed or secreted by 
the renal tubules, or modified by the kidney following filtration, then the quantity of that 
substance that appears in the urine per unit time, equals the quantity of substance that is filtered 
at the glomerulus. This is represented mathematically as: 
C x Pi = Ui x V 
Where C is the volume of plasma filtered at the glomeruli per unit time (or the volume of plasma 
that is completely cleared of the indicator/substance per unit time), Pi the concentration of the 
substance in the plasma, Ui the urinary concentration of the substance, and V the urinary flow 
rate.  
For an ideal substance C = GFR, and therefore: 
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There are two non toxic substances which fulfil these ideal criteria. They are both fructose 
polymers extracted from plants, called inulin and polyfructosan. Neither substance is endogenous 
in humans, and must therefore be continuously infused throughout the GFR measurement. In 
practice this involves administration of a bolus (adjusted to patient weight), followed by infusion 
at a constant rate to achieve stable plasma concentration (about 1 hour). The patients are also 
supplemented with an oral water load and periodic water to ensure adequate urine flow rate 
(ideally > 2ml/min). Once a stable plasma concentration of indicator/substance has been 
achieved, the patients empty their bladder completely, and urine samples are then taken at 
regular intervals (typically 30-60 minutes).  The plasma concentration of the indicator/substance 
is measured at the beginning and end of each period of urine collection. To minimise error, 
typically three to five determinations are made.   
 
3.1.1 Problems with the clearance concept 
 Plasma concentration 
Administration of exogenous substances (inulin/polyfructosan) requires an accurate infusion 
pump to maintain constant plasma concentrations, and waiting for the infusion to reach a steady 
concentration is time consuming.  
This can be countered with the use of endogenous substances, such as creatinine. This is a 
metabolic product of creatine and phosphocreatine, both of which are found almost exclusively 
in muscle
83
. However, whilst the plasma concentration of creatinine is relatively constant, and 
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displays little variation throughout the day, it is directly related to patient muscle mass and 
dietary protein intake
84
, and its production can be reduced in patients with hepatic disease
85
.  
Urine collection 
The most significant disadvantage of the clearance concept is the need for a measurement of the 
urinary flow rate, and subsequently a timed urine collection must be made. In practice the easiest 
way to achieve this is by passing a urinary catheter. Due to the general reluctance to catheterise 
patients with no direct clinical need, timed urine collections following induced dieresis are 
typically used.  
When performed on an unsupervised basis (such as in the outpatient setting), achieving complete 
and accurately timed urine collections is paramount. Typical difficulties encountered include: 
lost specimens, inaccurate timing such that the sample supplied does not correspond to a 24 hour 
collection period, and inclusion of urine already in the bladder at the start of the monitoring 
period. In addition, patients with urinary tract abnormalities or reflux may not be able to provide 
sufficient samples. The collection of urine samples in children poses its own difficulties and 
restrictions. 
Glomerular filtration rate and relationship to patient size 
One further significant problem with GFR estimations, is the physiological variation of GFR in 
healthy individuals of different ages and sizes
86
. It is widely accepted that renal data should be 
corrected for body surface area, using tables of height and weight, with an adult male surface 
area of 1.73 m₂ used as standard. This assumes that GFR increases as a linear function of body 
surface area. Obesity, oedema or anorexia can result in either under- or over-estimation of GRF 
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due to variation in weight, and subsequently ideal weight for height is used instead. Thus GFR is 
in essence expressed in terms of height only.  
When creatinine is used as the indicator, there are additional concerns as creatinine excretion, 
varies widely with body composition, in particular muscle mass, resulting in potentially incorrect 
estimations of GFR.  
 
3.1.2 Creatinine clearance and GFR 
Since the suggestion that endogenous creatinine clearance can be used instead of inulin or 
polyfructosan clearance, and that it equates to the GFR, this test has been popular in clinical 
practice. However, several inconsistencies in its use compared to the exogenous substances arise. 
They are due to variations in the production rate of creatinine, the accurate plasma analysis of 
creatinine and collection of urine samples, and the secretion of creatinine by the renal tubules
87
. 
Creatinine production 
Creatinine is produced by the non-enzymatic degradation of muscle creatine, which is 
synthesised in the liver and transported to muscle
88
. The main determinant of an individual’s 
creatine level is their muscle mass, with only a small proportion derived from dietary products 
(ie. meat). The production and consequent excretion of creatinine is therefore directly influenced 
by muscle wasting conditions, paralysis and of course dietary intake.  
Plasma creatinine measurement 
Due to the routine use of creatinine in the assessment of renal function, and in particular the 
estimation of GFR, it is important to understand the principal of the creatinine assay. 
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Creatinine is usually measured using the Jaffé reaction (see Figure 8). This involves reacting 
creatinine with alkaline picrate to form an orange-red coloured Janovsky complex
89
.  
 
 
Figure 8: The reaction of creatinine and picrate under alkaline conditions to form  a Janovsky 
complex; the basis of the Jaffé reaction. 
 
 
Unfortunately the creatinine concentration is generally overestimated in plasma, with consequent 
underestimation of creatinine clearance. This is because other chromogens which react with 
alkaline picrate, are present in plasma, and produce a similar colour to the Janovsky complex
89
. 
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This is particularly pronounced at low creatinine concentrations, and so the greatest effect is seen 
around normal creatinine values. To overcome this effect, the unwanted chromogens can be 
absorbed using Fuller’s earth or resins89, or more commonly dialysed off.  Alternatively rate-
dependent reactions can be used, based on the fact that the reaction of creatinine with picrate 
occurs faster than that of non-creatinine chromogens.  
Factors affecting creatinine plasma concentration and clearance 
When infused, creatinine is secreted by the renal tubule and usually the creatinine clearance 
equals or exceed the GFR (when accurately measure with inulin clearance techniques)
90
. More 
importantly is that this concept of increasing creatinine clearance to GFR steadily increases as 
the GFR falls and the plasma creatine rises, to the point that creatinine clearance may be more 
than twice the inulin clearance
90
. Thus overestimation of the GFR by creatinine clearance 
increases proportionally as the GFR declines.  
Creatinine re-absorption is not usual in humans, but can occur in states of low urine flow, such as 
congestive heart failure
91
. Further, it has been suggested that in the presence of significant 
proteinuria, the creatinine clearance can be significantly elevated
91
. Additionally, following the 
ingestion of meat subjected to prolonged stewing, it has been shown that the plasma 
concentration of creatinine can suddenly double
92
. The stewing of the meat converts the creatine 
to creatinine, and so in effect a creatinine meal is ingested. The effect is not reproduced by other 
methods of cooking meat, or with non-meat proteins.  
Creatinine clearance is directly affected by muscle mass changes, resulting in observed changes 
in estimated GFR. It has been demonstrated that urinary creatinine equilibrates three weeks 
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following a change in muscle mass
93
, making urinary creatinine unreliable for patients on 
different diets or when taking alternating levels of proteins.  
All of these factors combine to make creatinine clearance estimation through plasma and urine 
analysis unreliable in clinical practice. 
 
3.1.3 Plasma creatinine levels as an indicator of GFR (Cockroft and Gault formulation) 
Due to the difficulties of measuring inulin/polyfructosan clearances and obtaining accurately 
timed urine collections for creatinine clearances, the use of plasma creatinine to derive GFR has 
gained widespread clinical use.  
Unfortunately the relationship of plasma creatinine and GFR is non linear, such that for small 
reductions in GFR, plasma creatinine is a poor index of GFR, just where precision is needed 
most. Additionally, whilst GFR and creatinine clearance fall steadily with age, there is no 
corresponding rise in plasma creatinine, with levels substantially unchanged throughout adult 
life
94
. Due to these relative imprecisions, the estimation of GFR from plasma creatinine has 
limitations.  
Plasma creatinine also tends to overestimate the GFR at all levels of renal function, even in the 
presence of enhanced creatinine secretion with reduced GFR. Due to creatinine losses in the 
gastrointestinal system, and secretion of creatinine in the renal tubules, plasma creatinine will 
tend to overestimate the GFR in patients with reduced renal function
90
. Despite these limitations, 
plasma creatinine remains a popular test of renal function, principally due to its simplicity and 
wide availability.  
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Instead of using graphs to derive creatinine clearance and consequently GFR from plasma 
creatinine, several formulae have been developed to enable immediate and easy estimation of 
GFR. These are typically in the form of creatinine clearance, derived from plasma creatinine 
levels.  
The most widely used and most validated is the Cockroft and Gault formula
95
:  
 
Ideally plasma creatinine should be analysed by an automated process, and a correction factor of 
0.85 should be applied for women due to smaller creatinine production.  
However it should not be forgotten that estimation of GFR for plasma creatinine has multiple 
limitations, with estimation particularly unreliable in the old and the very obese, for reason 
discussed previously.   
 
 
 
 
 
 
 
49 
 
3.2 Other markers for the estimation of GFR 
ß2-microglobulin 
The kidney plays an important role in the disposal of peptides and small molecular weight 
proteins. This is principally by unrestricted filtration at the glomerulus, with pinocytic re-
absorption in the tubule and catabolism to the constituent amino acids. Therefore a large number 
of peptides accumulate in the plasma when renal function falls.  ß2-microglobulin is a small 
molecular weight protein that is freely filtered at the glomerulus, meaning the plasma 
concentration in health is low
96
.  This plasma concentration rises as the GFR falls in a linear 
relationship throughout the whole range of values, making it an excellent marker in renal 
dysfunction
97
.  The plasma concentration of ß2-microglobulin is not affected by muscle mass, 
sex or age as occurs with creatinine
97
.  
The principal reason for its lack of widespread clinical adoption has to date been the relative 
expense of the radioimmunoassay needed to measure its levels. Secondly, whilst the turnover of  
ß2-microglobulin is relatively constant in most patients, in those with lymphoid tissue tumours 
and some inflammatory conditions such as rheumatoid arthritis, there may be increased plasma 
concentrations due to increased production rather than reduced clearance
98
.  
Radionuclides 
Several radiolabelled chelates have been used to assess GFR in humans. Chief amongst them is 
99Tcm-DTPA (diethylene thiamine penta-acetic acid)
99
. They can be used as inulin substitutes in 
conventional infustion assessments of GFR. However most use avoids urine collections and 
infusions, and centres on boluses being given, followed by analysis of the disappearance curve 
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from the plasma measured using gamma cameras. However, the need for bolus infusion, access 
to expensive equipment, and exposure to ionising radiation, limits these studies from widespread 
clinical use.  
More recently, Cystatin C has gained popularity as an alternative endogenous marker of GFR 
 
3.3 Cystatin C 
Clinically, plasma creatinine and the calculated creatinine clearance are widely used as markers 
for GFR. The primary benefit is that they are cheap, and there is widespread availability to 
creatinine analysis on a routine basis. However, the accuracy of estimation of GFR with these 
methods is decreased by alterations in the metabolism and renal handling of creatinine, and the 
laboratory analysis of creatinine
100
. As previously stated, the ideal marker for GFR calculation 
should be endogenous, appear in the plasma at a constant rate, be freely filtered at the 
glomerulus, be neither secreted or absorbed by the renal tubule, and undergo no extra-renal 
elimination. A fast, reliable, and safe method of estimating the GFR is of significant value in 
clinical and research practice. Previous methods as previously discussed have many 
disadvantages. The low molecular weight protein Cystatin C meets many of these criteria, and in 
recent years developments have enabled Cysyatin C to be measured in a routine, accurate and 
reproducible method for clinical use
101
. 
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3.3.1 Cystatin C structure 
Cystatin C is one non-glycosylated polypeptide chain containing two disulphide bridges with 120 
amino acid residues (see Figure 9), and a molecular weight of 13.359 kDa
102
. The entire 
nucleotide sequence of the Cystatin C gene has been mapped and localised to chromosome 20, 
and has a stable production rate by most nucleated cells
103, 104
. Due to the low molecular weight 
Cystatin C is freely filtered at the glomerulus and reabsorbed and catabolised in the proximal 
tubule
105
. The urinary concentration of Cystatin C is therefore typically low.  
 
 
Figure 9: A Protein Data Bank (PDB) 3-D rendering of a molecule of Cystatin C 
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3.3.2 Role of Cystatin C 
Cystatin C is a proteinase inhibitor from the Family 2 of the cystatin superfamily
106
. It is present 
in all human biological fluids, with particularly high concentrations in seminal plasma and 
cerebrospinal fluid
106, 107
. The primary function appears to be protective, with prevention of 
degradation of connective tissue by intracellular enzymes leaking from dying cells
108
. 
Additionally Cystatin C has been demonstrated to play a role in the defence against both 
microbial and viral infections
109, 110
.  
 
3.3.3 Stability and storage of Cystatin C 
Plasma samples can be stored without degradation for up to seven days at room temperature, in a 
fridge, a freezer (-20°c), or up to six months in a freezer (-80°c)
111
. It is possible to prevent 
further degradation with the addition of proteinase inhibitors and preservatives. 
 
3.3.4 Factors influencing Cystatin C 
Cystatin C does not appear to be an acute phase reactant, with no discernible change in the rate 
of production of Cystatin C in patients with acute inflammatory conditions
112
.  
Although it was originally felt that Cystatin C levels were not affected by malignancy, recent 
evidence had shown raised serum levels in the presence of melanoma
113
. 
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There is currently no evidence to suggest that drugs used in clinical practice affect the plasma 
levels of Cystatin C, although in vitro studies have demonstrated a dose dependent increase in 
Cystatin C production following dexamethasone administration
114
. 
The principal benefits of Cystatin C over creatinine, is that its concentration in plasma can be 
interpreted in the absence of correction for age, height, weight and gender. Its serum 
concentration is also unaffected by dietary intake, and analysis is not affected in general by 
interfering factors in plasma.  
Cystatin C levels in plasma are therefore more reliable than sCr, due to fewer influencing factors.  
 
3.3.5 Cystatin C assays 
For accurate clinical use, Cystatin C assays must be automated for ease and free from interfering 
factors, which as previously discussed can compromise accurate creatinine estimation.  
The first estimation of Cystatin C occurred in 1979, and utilised immune-electrophoresis
107
. This 
was a complicated procedure using enzyme amplified single radial-immuno-diffusion, and took 
approximately two days to complete. Whilst accurate, there were too slow for realistic clinical 
use. 
It was not until 1994 that a suitably accurate, easy to perform, and quick automated assay for 
Cystatin C was introduced. This was the development of the latex-particle enhanced immune-
turbidimetric assay (PETIA)
101
. This was quickly followed by the latex-particle enhanced 
nephelometric immunoassay (PENIA)
115
.  
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These assays are precise, rapid and easy to perform for routine clinical practice. No interferences 
with other plasma factors have been reported, although there is a suggestion that bilirubin levels 
may affect the accuracy of PETIA
101
. 
 
3.3.6 Cystatin C and renal function 
Serum Cystatin C was first suggested as a marker of GFR in 1985, where serum Cystatin C 
levels were found to be as closely correlated to GFR as serum creatinine
116
. More recently, using 
immunoassay techniques the degree of correlation between a reference GFR procedure and 
reciprocal Cystatin C concentration in plasma, has been shown repeatedly to be superior to that 
of creatinine concentration
117-119
. Additionally, several studies suggest that Cystatin C may in 
fact detect subtle early renal injury before developing clinical significance, or detection by sCr 
assays, with a reduction in GFR of only 30% needed to produce a doubling of Cystatin C
120, 121
. 
For these reasons, Cystatin C is being used increasingly instead of creatinine as an accurate 
marker of GFR in a variety of clinical studies.  
Although Cystatin C is an accurate marker of established and evolving renal failure, there has 
been considerable interest recently in acute phase biochemical renal function markers, in 
particular neutrophil gelatinase-associated lipocalin (NGAL). Its ability to detect early renal 
dysfunction prior to overt clinical features, or rise in conventional biochemical markers has 
gathered most interest.   
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3.4 Neutrophil Gelatinase-Associated Lipocalin  
NGAL is a member of the lipocalin family of proteins. The lipocalins are typically small secreted 
proteins, with an ability to bind small hydrophobic molecules in a structurally conserved pocket 
formed by B-pleated sheet, to bind to specific cell surface receptors and form macromolecular 
complexes. NGAL is also commonly known as lipocalin 2, oncogene protein 24p3, NL 
(neutrophil lipocalin), and HNL (human NL). 
Human NGAL consists of a single disulphide bridged polypeptide chain of 178 amino-acid 
residues (see Figure 10), with  a calculated molecular mass of 22 kDa, but glycosylation 
increased its apparent mass to 25 kDa
122
. 
In neutrophils and urine it occurs as a monomer, with  a small percentage of dimer and trimer, 
and also in complex with 92-kDa human neutrophil type IV collagenase [matrix 
metalloproteinase-9 (MMP-9)]
123
. 
NGAL was originally isolated from activated human neutrophils
122
, but it is also expressed at 
low levels in other human tissues, including the kidney, prostate, respiratory and alimentary tract 
epithelia
124, 125
. It is strongly expressed in adenomas and inflammatory bowel epithelia
126
, 
adenocarcinomas of the breast
127
 and urothelial carcinomas
128
. 
Because of its small molecular size, and ability to resist degradation, NGAL is readily excreted 
and detected in the urine. Urinary levels correlate directly with plasma /serum levels whatever 
the cause for increased NGAL production.  
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Whilst the functions of NGAL are not fully understood, it appears to be upregulated in cells 
under stress, such as from infection, inflammation, ischaemic change or neoplastic 
transformation. 
 
Figure 10: A Protein Data Bank (PDB) 3-D rendering of a molecule of NGAL 
 
3.4.1 NGAL and the kidney 
Dramatic upregulation of NGAL was first observed in rat proximal tubule cells after ischaemia 
re-perfusion injury, indicating that NGAL may be a marker of acute renal injury. Subsequently 
raised plasma levels were found to strongly correlate with decreased renal function in patients 
with vasculitis
129
 and renal injury following nephrotoxic agents
130
. Further studies observed that 
urinary NGAL levels may serve as an early marker for ischaemia related renal injury in children 
following cardiopulmonary bypass
131
, and raised urinary and serum NGAL levels have also been 
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observed in patients with established renal failure, and in patients with acute renal failure 
following renal transplantation
132
.  
Consequently a variety of renal disorders have been shown to be associated with raised plasma 
and urinary NGAL levels, with plasma and urinary levels closely correlated in acute conditions. 
It is speculated that renal expression of NGAL, and thus urinary and plasma levels, will be 
dramatically increased following renal injury sufficient enough to result in acute renal failure, 
acute tubular necrosis or acute tubule-interstitial nephropathy.  
NGAL levels typically rise within two hours of the renal insult, peaking up to 48 hours, before 
gradually returning to baseline levels, making NGAL an early and sensitive biochemical marker 
for acute renal injury.  
 
3.4.2 Collection of NGAL and assay procedure  
Determination of NGAL requires 10 μL of plasma, serum or urine. Blood samples are collected 
into EDTA tubes, and then spun in a centrifuge to component parts. Specimens can be stored 
indefinitely at -80°c.  
A 96 well pot and ELISA reader are required for assay, and all component parts are supplied in a 
pre packed AntibodyShop NGAL rapid ELISA test kit® (see Figure 11). The assay can be 
performed in less than 1 hour (see Figure 12). 
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Figure 11: NGAL Rapid Elisa Kit®, Antibody Shop, USA 
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Figure 12: The NGAL assay protocol 
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3.4.3 Interpreting NGAL results 
For calculation of results the exact values of the calibrators printed on the quality control 
certificate should be used. The finding of a raised NGAL level cannot be independently 
diagnostic of any single pathology, since a variety of independent pathologies are associated with 
raised levels of NGAL, although it is highly suggestive of renal dysfunction. 
Raised NGAL levels are associated with renal failure as demonstrated (see Table 5). Therefore 
an NGAL concentration >400 ng/ml in plasma is highly likely to be due to renal injury, that may 
result in acute renal failure. NGAL levels lower than this may indicate either no or slight renal 
injury. A sudden rise in NGAL levels above previous values may indicate renal injury, even 
when the cut-off value is not exceeded, and close surveillance of renal function is recommended. 
 
Sample Plasma 
Cutoff value 400 ng/ml 
Diagnostic specificity 96.3% 
Diagnostic sensitivity 84.8% 
Positive predictive value 93.1% 
Negative predictive value 83.9% 
 
Table 5: Interpreting NGAL results 
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Chapter 4. Long term renal function following EVAR (Study 1 & 2) 
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4.1 Introduction 
Endografts have evolved considerably in the 20 years since Parodi and colleagues described the 
endovascular repair of an AAA
15
. Some first generation endografts were prone to stent fracture 
and subsequent device migration, resulting in failure to exclude the AAA
32, 33, 35
. This has led to 
several technical modifications in endografts with an aim to improve overall outcome. 
Perhaps the most significant technical modification to the current generation endografts has been 
the addition of uncovered bare metal stent struts that extend beyond the fabric covered graft 
proximally and cross the renal ostia. This allows the fabric covered graft to sit just below the 
renal arteries, covering the full length of the aneurysm neck, and the stent struts to utilise the 
non-aneurysmal proximal aorta. Both these factors enable a more secure proximal fixation, 
preventing device migration
46
. By utilising the non-aneurysmal proximal aorta they also allow 
treatment of patients with short aneurysm necks
58
.  
The impact of crossing the renal ostia has led to considerable concern regarding renal blood 
flow, and subsequent possible renal damage, with many early studies suggesting high levels of 
renal infarction and renal failure in the immediate post operative period
50, 133
. This has resulted in 
much controversy and ongoing research to assess renal safety, especially with regard to long 
term renal safety. 
Current research suggests that short to medium term renal function is not significantly altered 
following trans-renal endograft deployment
43, 44, 50-56, 134
, however further work is need to 
determine long term renal safety.  
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Although these studies demonstrate no clear evidence of adverse renal events to date, the 
biochemical assessment has relied almost exclusively on sCr and the Cockroft-Gault derived CrC 
(see Chapter 3).  
Several studies have demonstrated the weaknesses of sCr and the Cockroft-Gault derived CrC in 
the assessment of renal function, and that renal function (GFR) may in fact have to decrease by 
up to 50% prior to any detectable change in sCr
117, 120
.  
Recently the low molecular weight protein Cystatin C has been validated as a superior 
endogenous renal marker to sCr. Several studies suggest that Cystatin C may in fact detect subtle 
early renal injury before developing clinical significance, or detection by sCr assays, with a 
reduction in GFR of only 30% needed to produce a doubling of Cystatin C
120, 121
. 
Cystatin C may therefore demonstrate previously undetected subtle renal dysfunction in the mid 
to long term for patients who have had SR-EVAR, but for whom the standard measurements of 
sCr and CrC are unchanged.  
These studies aim to directly compare delayed renal function following SR EVAR with IR 
placement, using the conventional measurements of sCr and CrC, and to assess renal function 
following EVAR using Cystatin C as a more sensitive marker of renal function. Additionally 
they aim to confirm Cystatin C as a valid marker of renal function (GFR) in the aneurysm 
population.   
 
 
 
64 
 
4.2 Patients and methods 
 Study 1 
One hundred and eighty patients consecutively undergoing EVAR for AAA at this centre over a 
six year period (1995-2001), were identified from a prospectively maintained EVAR database 
detailing basic information such as patient identifier details, date of operation, and type of EVAR 
device used. Patients were grouped according to the level of proximal fixation of the EVAR, 
either infra-renal (IR) or supra-renal (SR). The type of proximal fixation used was primarily due 
to availability of endografts at the time of the procedure, and not secondary to patient co-
morbidities or aneurysm morphology. Most of the earlier deployments consisted of IR grafts, 
with later deployments comprising SR grafts, which gained favour as the endograft modality of 
choice at the Northern Vascular Centre. Those patients unsuitable for IR EVAR prior to the 
introduction of SR endografts had simply been offered open AAA repair. Therefore the groups 
were in essence deployed in chronology, with SR deployment tending to follow IR.  
The case notes for every patient were retrieved, and reviewed exhaustively. A separate database 
was constructed containing full data with respect to each patient. Patient demographics such as 
age, sex, ASA grade, co-morbidities, tobacco use, initial AAA size, renal function pre-
operatively, and operative factors such as operation length, blood loss and contrast load were 
recorded, as well as any interventions or complications in the post-operative period.  All patients 
had been recalled on at least a yearly basis following their procedure, and had undergone blood 
sampling for renal function analysis, allowing annual assessment of renal function up to 10 years 
to be included in the constructed database. If the biochemical renal markers were not clearly 
documented in the notes, then a review of the Northern Vascular Centre’s computerised 
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pathology results programme, allowed their determination at the appropriately documented 
follow up collection time point. The data was collected in this manner (from a single source), to 
ensure validity and minimise the potential for error. As a historical record of a patient’s 
treatment, created at the time of treatment by physicians, the case notes are the most reliable 
form of documentation for each aspect of treatment and follow up care. All renal markers 
sourced from the computerised pathology results programme had been produced in a validated 
and accredited NHS Hospital pathology laboratory, and were matched to the specific follow up 
time points. 
Between 2006-2007 (the period of the study), all patients still attending their yearly follow up 
were approached, provided with an information sheet (see Appendix B & C), and invited to enrol 
in the study. Consent was obtained (see Appendix E) for the purpose of blood analysis of renal 
function, and case note review for the purpose of publication. Those patients who failed to attend 
their yearly appointment, were contacted where possible, and arrangements were made for them 
to attend the out-patients for review at a time of their convenience. A single blood test was taken 
for the purpose of sCr measurement and CrC calculation to assess renal function up to 10 years 
following EVAR. 
All patients having undergone successful EVAR between 1995-2001, were considered eligible 
for inclusion into this study. The only exclusion criteria were complete absence of paired renal 
data at any time point (such as lost to follow up), conversion to open AAA repair at time of 
original operation, and if there was less than 12 months renal follow up post-procedure. 
Full ethical approval for the study was granted by the Northumberland Local Research Ethics 
Committee, reference 06/Q0902/40. 
66 
 
Study 2 
This study was a continuation of a previous prospective controlled trial performed at the 
Northern Vascular Centre (Freeman Hospital, Newcastle, UK) during a twelve month period 
commencing 2002 (Newcastle & North Tyneside JEC ethics approval 2002/150)
135
. 
During the initial study period, all patients had been participants in the EVAR-1 Trial
17
, and as 
such had been randomised to either Open AAA repair (OR) or EVAR as per the EVAR- 1 trial 
protocol. This simply meant that any patient medically fit enough for an open AAA repair had a 
50: 50 chance of either EVAR or OR, with randomisation occurring centrally at the EVAR Trial 
headquarters, and not at the Northern Vascular centre. All consecutive patients undergoing AAA 
repair during this twelve month period were approached for inclusion into the study, with only 
pre-operative renal failure requiring replacement therapy precluding enrolment. Patients were 
followed for a twelve month period during which serial blood tests for analysis of sCr, CrC and 
CC were taken at 3,6 and 12 months. At enrolment to the study, patient factors recorded included 
sex, age, weight, smoking habit, AAA size and significant co-morbidities. EVAR related 
procedural variables included device type, deployment success and contrast load. During the 
initial study no significant difference was found between groups with respect to Cystatin C and 
renal function
135
. 
All patients enrolled in the initial study were subsequently followed up on a yearly basis 
following surgery, as per EVAR-1 Trial protocol
17
. Between 2006-2007 all original patients still 
attending follow up were approached (corresponding to their fourth year of follow up), provided 
with an information sheet (see Appendix A), and consented (see Appendix E) for blood analysis 
of renal function and CC, and case note review for the purpose of publication. Following case 
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note review a database was created containing general patient demographics (age, sex, co-
morbidities, tobacco use and aneurysm size), as well as contrast load used intra-operatively. 
Those patients who failed to attend their yearly appointment, were contacted where possible, and 
arrangements were made for them to attend the out-patients for review at a time of their 
convenience. 
A single blood test was performed allowing analysis for sCr, CrC and CC for the purpose of 
renal function assessment. 
Renal function was recorded using sCr was analysed on an Olympus 2700 multi channel analyser 
(Jaffé reaction based) using the manufacturers supplied reagents, providing a between batch 
imprecision of less than 2% for each analyte. Considered a routine blood test, analysis of sCr was 
performed by the Pathology Laboratory staff at the Northern Vascular Centre.  
Creatinine clearance (CrC, ml/min) was calculated using using the validated Cockroft-Gault 
formula
95
:  
 
A gender correction factor (multiplication by 0.85) was applied for female patients.  
Cystatin C was analysed with PETIA (latex particle enhanced immunoturbidimetric assay). A 
clotted blood sample was collected, then spun for 10 minutes at 3000 rpm. Serum was withdrawn 
and stored at -80°C for later batch analysis. CC was determined by PETIA using the Cobas 
MIRA Plus automated analyser®. The DAKO Cystatin C PETIA kit® contains polystyrene 
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particles chemically coupled with rabbit antibody against human CC. When these 
immunoparticles and CC react, agglutinates form with a concomitant change in the absorbance 
signal at 340 nm. The CC concentration can then be determined via a calibration curve with a 
typical coefficient of variance of less than 8%. The assay is rated with a specificity of 96.3%, 
positive predictive value of 93.1%, and a negative predictive value of 83.9%. Determination of 
CC was performed by the principal investigator under the direct guidance of Dr. R. Peaston, 
Senior Biochemist (Northern Vascular Centre, Newcastle, UK), and was performed in the 
pathology laboratories of The Northern Vascular Centre. There was no blinding to the assay. 
Full ethical approval for the study was granted by Northumberland Local Research Ethics 
Committee (reference 06/Q0902/40). 
 
 
 
 
 
 
 
 
 
69 
 
4.3 Data analysis 
All data was anonymised and initially stored within a Microsoft Excel® Spreadsheet on a 
password protected NHS Trust computer, with access granted only to the primary investigator 
and research supervisor. Relevant data was transferred as necessary to Minitab 14® (Minitab 
Inc., PA, USA) statistical software for statistical and graphical analysis. 
Median values were used for continuous variables, and means for non-continuous variables. 
Renal data is represented by box and whisker plots, with boxes representing inter-quartile ranges, 
the intervening bar representing the median value, and whiskers representing the 90% range.  
For serial comparison of renal function two statistical methods were employed. The 1- sample 
Wilcoxon Test compared non-parametric continuous variables (such as within groups), and the 
Mann-Whitney U-Test compared 2 sample non-parametric variables (such as between groups). A 
Bonferroni correction factor was used for both when repeated analysis was made.  
The 2-sample t-test was employed for comparison of continuous variables. Observational 
comparisons with non-continuous data were made using the chi-square test. 
Change in CrC over time between the two groups (change in renal function over time), was 
compared using the technique of summary measures (co-efficients of the change in CrC over 
time), and data was compared at each time point using the 2-sample t-test.  
Linear regression was used when appropriate to assess the association between variables, with 
the relationship strength given by the Pearson correlation co-efficient, r.  
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Results were considered statistically significant if p<0.05, with NS meaning not statistically 
significant.  
Population sizes needed were calculated based on a difference between groups of one standard 
deviation (20 umol/L and 0.18 mg/L for sCr and CC respectively), being clinically significant. 
This would equate to a difference in the biochemical renal markers of approximately 20% 
between groups, or 20% increase above baseline values, a level which most studies consider 
clinically significant. When powered to 80%, the required numbers for each group in both study 
1 & 2 to gain significance are 17 patients.  
Data set completeness was achieved for missing data (ie. those patients lost to follow up), by 
comparison of the pre-operative demographic data (see Chapter 4.2), and rates of re-intervention 
following surgery at each specific time point for the remaining patients. If there were more than 
17 patients in each group and the above data was comparable, with no statistically significant 
differences between the groups at that time point, then comparison of renal function was made 
between the groups. 
All statistical methods employed were discussed with and approved by with Professor Matthews 
(Department of Mathematics and Statistics, University of Newcastle upon Tyne, Newcastle, UK) 
as part of the application and enrollment procedure for entry to the M.D. programme. 
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4.4 Results 
Study 1 
During the 6 year study period one hundred and eighty EVAR’s were performed. There were 88 
IR endografts, and 92 SR endografts deployed. Paired renal data was available for one hundred 
and thirty patients in total, with the number of patients with paired renal data decreasing on an 
annual basis from time of EVAR (see Table 6). 
Time interval since EVAR (months) IR(n) SR (n) 
0 88 92 
12 58 46 
24 50 38 
36 24 26 
48 24 23 
60 22 21 
72 21 20 
84 20 20 
96 13 5 
108 11 1 
120 6 0 
 
Table 6: Group specific number of patients (n) with paired renal data at annual review following 
EVAR 
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IR endografts were from a variety of manufacturers, but the majority were Boston Scientific 
Vanguard® devices, whereas SR devices were exclusively Cook Zenith® devices (see Table 7). 
Group specific demographics as well as aneurysm size, ASA grade, operation length, blood loss, 
contrast load, follow up length, and pre-operative sCr and CrC are reported (see Table 8). Both 
groups were comparable in respect of demographics, and operative factors, although there was a 
statistically significant longer follow up period with the IR group (p<0.05, 2-sample t-test), 
reflecting the earlier availability of these endografts compared to SR. There were no statistically 
significant differences between the groups with respect to renal risk factors (age, co-morbidities, 
pre-existing CRF), or operative factors predisposing to long term renal failure (operation length, 
contrast load, blood loss) (all p=NS, chi-square test). 
Device type IR Group SR Group 
Vanguard (Boston Scientific) 49 - 
Talent (Medtronic) 12 - 
Excluder (Gore) 8 - 
Mintec 6 - 
Endologix (Powerlink) 5 - 
EVT 4 - 
Zenith (Cook) - 92 
Totals 88 92 
 
Table 7: Group specific endograft device types 
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 IR Group (n=88) SR Group (n=92) 
Median age (years) 
Range 
73 
56-87 
74 
56-90 
Sex; M: F 78: 10 83: 9 
Co-morbidity: 
IHD 
Diabetes 
CRF 
 
40 
19 
11 
 
46 
20 
9 
Tobacco use 26 25 
Median AAA diam. (mm) 
Range 
60 
45-145 
65 
41-100 
ASA Grade; Median 3 3 
Op length (mins); Median 
Range 
130 
60-380 
125 
70-330 
Blood loss (mls); Median 
Range 
170 
0-1350 
155 
0-545 
Contrast load (ml); Median 
Range 
193 
105-405 
185 
95-370 
F/U length (months); Mean 43.9 31.4 
sCr (μmol/L); Median 
Range 
113 
72-243 
108 
75-307 
CrC (ml/min); Median 
Range 
57 
22-102 
58 
22-139 
 
Table 8: Group specific demographics 
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Between 48 and 84 months there was no statistically significant elevation in sCr compared to 
pre-operative levels (p=NS, 1-sample Wilcoxon) for either group. Similarly there was no 
statistical difference between each group at any specific time interval (p=NS, Mann Whitney U-
Test) (see Graph 1). 
CrC has apparently remained stable in long term follow up. Statistical analysis of CrC at each 
time interval both within and between the two groups has shown no significant change in CrC 
over time following EVAR irrespective of proximal fixation type (see Graph 2).  
Renal function up to 10 years post endograft deployment for both SR and IR groups was also 
assessed. There was no apparent deterioration in renal function up to 120 months following IR 
deployment, and 96 months following SR deployment, as measured by either sCr (μmol/L) or 
CrC (ml/min) (see Graphs 3 & 4). Statistical analysis was not possible in either group beyond 84 
months due to insufficient patient numbers [less than 17 per group and per time period (see Table 
6)]. 
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Graph 1: Fixation specific late sCr (all p=NS, Mann-Whitney U test/1-Sample Wilcoxon) 
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Graph 2: Fixation specific late CrC (all p=NS, Mann-Whitney U test/1-Sample Wilcoxon) 
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Graph 3: Fixation specific sCr to 10 years (all p=NS, Mann-Whitney U test/1-sample Wilcoxon) 
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Graph 4: Fixation specific CrC to 10 years (all p=NS, Mann-Whitney U test/1-sample Wilcoxon) 
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Comparitive change in renal function over time 
As CrC decreases over time in any population, it is more valuable to compare the comparative 
change in renal function (ΔCrC) over time between the two groups.  
Whilst the previous analysis compares renal function with sCr and CrC at specific time points, 
using the Pearson Correlation Co-efficient (change CrC/year), it is possible to compare both 
groups over the whole time period (see graph 5).  
The Pearson Correlation Co-efficient was -0.76 and -1.28 (ml/min per year) for the IR group and 
SR group respectively (p=NS, 2-sample t-test).  
Although the SR group appeared to have a greater decline in renal function over time, this was 
not found to be statistically significant in our study population.  
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Graph 5: Comparative change in CrC over time, Pearson Correlation Co-efficient r = -0.76 and   
-1.28 (ml/min per year) for IR and SR respectively (p=NS, 2-sample t-test) 
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Group specific complications and re-interventions 
When considering the long term renal function following EVAR, it is important to consider 
EVAR specific complications, which may affect renal function post endograft deployment. Most 
of these complications are treated with a further endovascular procedure, often requiring re-
cannulation of the aorta, and the administration of intravenous contrast agents for the purpose of 
radiological imaging. The typical EVAR specific complications include endoleaks, graft 
migration, endograft limb disconnect, and endograft thrombosis, and these may occur at varying 
times post endograft deployment (see Table 9). During the study and follow up period, 40% 
(35/88) of the patients in the IR group underwent at least one post EVAR re-intervention with a 
mean interval to intervention of 47.7 months. There were less re-interventions in the SR group, 
with only 9% (8/92) undergoing at least one re-intervention, with a mean interval to intervention 
of 31.0 months. This certainly corroborates recent evidence that endografts with trans-renal 
fixation (SR group), are less prone to device failures, and consequently the need for re-
intervention, however it must be remembered that since the IR and SR group were essentially 
deployed chronologically, then this discrepancy can also be explained by the more recent 
technological advancements of the SR endografts.  
Although there are differences in complication and re-intervention rates between the groups, 
these are not born out in long term differences in renal function. 
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 IR Group  
 
SR Group  
Re-intervention type 
& order of intervention 
No. Patients 
(n) 
Mean interval to 
intervention 
(months) 
No. Patients 
(n) 
Mean interval to 
intervention 
(months) 
Endograft limb 
extension: 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
 
19 
5 
1 
 
 
47.7 
81.6 
58.0 
 
 
1 
1 
- 
 
 
31.0 
39.0 
- 
Conversion to AUI: 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
1 
3 
- 
 
60.0 
71.3 
- 
 
- 
- 
- 
 
- 
- 
- 
Proximal aortic cuff 
insertion: 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
 
8 
1 
1 
 
 
55.3 
33.0 
48.0 
 
 
1 
- 
- 
 
 
75.0 
- 
- 
Limb thrombolysis: 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
- 
1 
1 
 
- 
14.0 
20.0 
 
1 
- 
- 
 
1.0 
- 
- 
Conversion to open 
AAA repair 
(rupture/infection): 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
 
4 
- 
- 
 
 
53.5 
- 
- 
 
 
 
2 
- 
1 
 
 
19.0 
- 
33.0 
Embolisation of 
endoleak: 
1
st
 intervention 
2
nd
 intervention 
3
rd
 intervention 
 
 
3 
2 
1 
 
 
10.0 
15.0 
70.0 
 
 
3 
2 
- 
 
 
39.0 
52.5 
- 
 
Table 9: Group specific late complications following EVAR 
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Study 2 
52 consecutive patients with AAA’s were recruited into the original phase of this study (24 
EVAR and 28 OR) in 2002, with no statistically significant differences between main patient 
demographics for each group, and both study groups analogous with respect to existing co-
morbidities and tobacco use (see Table 10). Whilst no patient required pre-operative renal 
replacement therapy (dialysis), those with renal impairment, simply defined as sCr beyond the 
normal reference range, but not requiring dialysis, were not excluded. 
There were no detectable differences biochemically between the study and control group prior to 
surgical intervention, with pre-operative renal function comparable between groups and no 
statistically significant difference detected (see Table 11). 
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 EVAR (n=24) OR (n=28) 
Age (years) 
Median 
Range 
 
74 
64-83 
 
75 
52-87 
Sex (M:F) 21:3 23:5 
Co-morbidity 
IHD 
HTN 
Diabetes 
CRF 
 
12 
11 
6 
4 
 
11 
15 
4 
5 
Tobacco use 6 8 
Aneurysm size (mm) 
Median 
Range 
 
62 
55-85 
 
63.5 
44-103 
Contrast Load (ml) 
Median 
Range 
 
163 
110-350 
 
- 
- 
 
Table 10: Group specific demographics. 
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 EVAR (n=24) OR (n=28) 
Renal function pre-operatively 
sCr (umol/L) 
CrC (ml/min) 
Cystatin C (mg/L) 
 
110.5 
61.8 
1.04 
 
110.5 
54.9 
0.96 
 
Table 11: Mean pre-operative renal assessment values. All p=NS, 2-sample t-test 
Stent deployment was successful in all but one case in the study series. Post EVAR deployment 
the Zenith® stent slipped proximally and partially covered the left renal artery with the covered 
portion of the endograft. The patient subsequently became oliguric, which did not respond to 
aggressive fluid resuscitation, and the patient became anuric. By day three post EVAR they were 
permanently dependent on dialysis. There were no renal complications observed in the open 
repair group following surgery. Although temporary supra-renal clamping was required in two 
cases to gain proximal control, there were no adverse sequelae.  
There was one death in the early post-operative period for both groups, which was not 
specifically aneurysm related. The patient appeared to recover well following EVAR and was 
discharged on day 6 post-operatively.  Within days they were readmitted to hospital with severe 
pneumonia, and ultimately succumbed to multi organ failure following a short stay on the 
Intensive Care Unit. 
At 4 years following AAA repair, and during the current study period, it was possible to re- 
recruit 34 patients (17 EVAR and 17 Open repair), for analysis of long term renal function 
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following AAA repair. Of the 18 missing patients from the original cohort, 8 were dead, and 10 
were lost to follow up, at this time point. None of the deaths were attributed to renal dysfunction, 
or aneurysm specific complications, and the most common reason for patients lost to follow up 
was a geographical change of domicile. There were no instances of re-intervention for 
complications in any of the patients. 
 CC and long term renal function 
At 4 years post AAA repair, renal function was comparable between the two study groups (see 
Table 12, Graph 6), with no statistically significant difference in either CrC or CC between the 
EVAR group and the control OR group detected (p=NS, Mann-Whitney U-test), or between 
earlier time points (p=NS, 1-sample Wilcoxon test) 
. 
 EVAR (n=17) OR (n=17) 
Renal function at 4 years 
sCr (umol/L) 
CrC (ml/min) 
Cystatin C (mg/L) 
 
112.75 
55.4 
1.06 
 
112.94 
55.5 
1.12 
 
Table 12: Mean post-operative renal assessment values (all p=NS, Mann Whitney U-Test) 
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Graph 6: Group specific renal function 4 years post treatment, all p=NS (Mann Whitney U- test) 
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Validation of CC as a renal marker in long term aneurysm follow up 
Although previously well described as a marker of renal function (GFR), it is important to assess 
the relationship between CC and estimated GFR in the AAA population, in case this population 
in particular possess confounding factors which could affect its accuracy. Using the estimated 
GFR for each patient (Cockroft-Gault derived CrC), and the routine biochemical marker sCr, the 
observed relationship between CC and renal function in the AAA population is demonstrated 
(see Graph 7). This study demonstrates a statistically significant relationship between sCr and 
CC (r=+0.9), and CrC and CC (r= -0.9), for both p<0.05 (Pearson correlation co-efficient), 
suggesting that CC is a valid index of excretory renal function (GFR) in the AAA population. 
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Graph 7: Variation of sCr and CrC with CC (p<0.05, Pearson Correlation co-efficient) 
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4.5 Discussion 
Since the advent of proximal bare metal stent struts crossing the renal ostia (to improve 
endograft durability and reduce migration rates), concern has arisen regarding the potential 
adverse effects on renal function. Initial concern centred on the metal struts partially covering the 
renal ostia, altering the renal blood flow, and causing renal dysfunction. Although partial 
coverage of a unilateral renal ostia occurs in up to 40% of cases, and 9% bilaterally
37
, early 
laboratory studies using animal models suggested that the placement of bare metal stents across 
the renal ostia (SR-EVAR) was at least safe in the short term
40, 41
.  
These early studies were soon followed by reports from several centres, which assessed mid- 
term renal function following SR-EVAR
49, 51, 134
. Unfortunately these early reports invariably 
involved study groups of only SR-EVAR patients, with no control groups for comparison, 
leaving a need for further evaluation of fixation specific renal outcome 
The first report of fixation specific renal outcome (comparing SR and IR fixation), was published 
by Kramer et al. in 2002 
50
. In this study post-operative CT images of 99 patients having 
undergone either SR or IR-EVAR were reviewed up to 12 months following endograft 
deployment. They found no increased risk of adverse renal events (infarcts), with the SR-fixation 
group.  
In the studies that followed, there was a common reliance on the use of insensitive sCr and CrC 
(Cockroft-Gault derived), to assess renal function. As previously discussed there are several 
limitations with the use of sCr as an indicator of renal function. Principally sCr is formed by the 
conversion of muscle creatine and phosphocreatine, and therefore its production is variable, and 
dependent on many external factors, such as diet, sex of patient, muscularity and surgical 
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intervention. Whilst the calculation of creatinine clearance (CrC) using the Cockroft-Gault 
formula
95
 has gone some way to correct these variables, it has been shown that GFR may have to 
fall by up to 50% prior to any associated rise in sCr and subsequent decrease in CrC
136, 137
. Hence 
sCr and CrC may remain within normal limits even in the presence of considerable renal 
dysfunction. Additionally the estimation of sCr itself, performed using the Jaffé reaction and 
colorimetric assay, may be altered by the presence of other chromogens in plasma, such as 
plasma proteins, resulting in falsely high estimations of sCr, and inaccurate CrC calculations.  
To overcome these limitations this study utilised both sCr and CrC, as well as cystatin C to 
assess long term renal function following fixation specific EVAR. Cystatin C is a low molecular 
weight protein produced by all nucleated cells. It is unaffected by patient sex or muscle mass, is 
freely excreted and metabolised by the kidney, and has been proposed as a more accurate 
estimate of GFR. The biochemical level of CC has been shown to double with even modest 
decreases in GFR  of up to 30%
121
, and as such CC should be able to detect mild renal 
dysfunction, previously missed by sCr and CrC. 
In Study 1, analysis of sCr and CrC values up to 8 years following EVAR, suggests no 
significant deterioration in renal function over time irrespective of proximal fixation type for the 
endograft. Additionally, both groups demonstrated a comparative change in renal function over 
time equivalent to the generally accepted deterioration of 1 ml/min per year (for the general 
population over the age of sixty five)
95
, suggesting no accelerated decrease in estimated GFR 
following EVAR, regardless of proximal fixation type. Although this would seem at first glance 
to contradict the previous findings (of stable sCr and CrC in long term follow up), graphical 
analysis of long term renal function for both groups did show a trend towards decreasing renal 
92 
 
function over time, although never reaching statistical significance. While there were insufficient 
patients to statistically assess renal function up to 10 years following EVAR, there did not appear 
to be any obvious difference in long term renal function between groups. In Study 2 it was 
possible to re-recruit 34 patients 4 years following original surgery. Of those deaths in the period 
between studies, none were from renal dysfunction or aneurysm related complications, and no 
patient required re-intervention for post operative complications. Up to 4 years following 
surgery, there were no clinical or statistically significant differences in renal function detectable 
between either group, and CC correlated well with renal function in the aneurysm population.  
Although relatively small numbers of patients were analysed in Study 1 from 48 months 
onwards, it is important to remember that there were sufficient numbers for statistical analysis up 
to 84 months, with a mean follow up of 40.5 months, longer than most similar studies at the time 
of writing (see Table 2). Since the AAA population are elderly, with significant co-morbidities, 
this should be considered long term renal follow up, as life expectancy longer than 10 years 
following AAA repair is likely to be low.  
The decision regarding proximal fixation type in Study 1 was independent of aneurysm 
morphology (determined by contrast enhanced CT scanning), and decided by the commercial 
availability of devices at the time on implantation [SR devices were not employed until nearly 3 
years (60 IR endografts) after the commencement of EVAR procedures]. Patients were not 
randomised to any particular group, rather the one providing the most clinically appropriate and 
cost effective solution. Subsequently most of the earlier EVAR’s performed by this centre were 
of IR type. Therefore the IR patients were theoretically exposed to the ‘learning curve’ of a new 
procedure, and the earlier generation, less advanced endografts. Renal dysfunction risk factors, 
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such as patient demographics (age, co-morbidities and pre-existence of CRF), and operative 
factors (blood loss, operation length and contrast load), were comparable and analogous between 
groups, with no statistically significant difference detected, other than mean follow up periods. 
These similarities were despite the earlier generation endografts (IR group) theoretically having 
an increased risk, in particular to operative risk factors, due to this ‘learning curve’. Although 
there were significantly more re-interventions in the IR group, a finding not unsurprising in early 
generation less advanced endografts, this did not appear to significantly affect long term renal 
function. All endografts deployed in Study 2 were of SR design, consistent with the preference 
of The Northern Vascular Centre for a specific make of endograft during the study period. 
Recent publication of the UK EVAR Trial results confirms our findings from Study 1 & 2. The 
UK EVAR Trial participants have reported no statistically significant difference in decrease in 
eGFR up to  a mean follow up of 3.6 years, between either EVAR or open repair (OR) groups (-
1.13 vs. -1.00 mL/min/1.73 m per year respectively), suggesting no long term difference in renal 
function following EVAR
138
. Although their data compared EVAR with open AAA repair, as in 
Study 2 (which found no significant difference in eGFR between groups), their deterioration in 
renal function over time was comparable to that demonstrated Study 1, and came from over 1000 
patients having had a variety of IR and SR devices implanted. 
Follow up of patient groups over long periods of time presents its own problems and 
complications. AAA patients tend to be aged with multiple co-morbidities. It is inevitable that 
significant numbers of patients will succumb to these over long periods of time. To ensure 
adequate numbers for long term follow up, there must be considerable sized groups from the 
outset. From the very first year following treatment, patient numbers decreased in the follow up 
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period, although it was still possible to recruit sufficient numbers in each study, to allow 
meaningful statistical analysis. If the patient did not attend follow up, then attempts were made 
to contact them, and arrange a more suitable time. If it was not possible to get data at that 
specific time point, then comparison of the demographics and renal confounding variables for all 
patients with data at each individual time point was performed. This was undertaken to prevent 
bias from high loss to follow up, and was felt that if the groups were still comparable, with no 
statistically significant difference between them (especially with respect to renal confounding 
variables), then comparison and analysis of renal function could occur.  
Unfortunately the only routine renal biochemical markers used in the follow up of EVAR 
patients in this centre since 1996 was sCr. This therefore limited Study 1 to the continuing use of 
sCr, and the Cockroft-Gault derived CrC to assess long term renal function. Continued and long 
term analysis of Cystatin C in the EVAR population seems unlikely beyond the 4 year mark, as 
there will be insufficient numbers for accurate statistical analysis beyond this point. 
One of the weaknesses of both studies was the absence of control groups. Study 1 would have 
benefitted from a control group of open AAA repairs over the same time periods. This would 
have allowed long term analysis of renal function following EVAR, and direct comparison to an 
AAA population who don’t have the potential renal risks of EVAR (operative risk factors, 
contrast loads at follow up, re-intervention for complications). Study 2 would have benefitted 
from a control group of non AAA patients, such as those undergoing major abdominal surgery, 
to allow comparison with a population who have no AAA associated risk factors. 
Whilst there was no formal renal protection policy within the Northern Vascular Centre during 
the period of the studies, every effort was made to avoid renal hazards. All patients had urinary 
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catheters and central venous pressure monitoring to enable accurate fluid management peri and 
post-operatively. Maximum effort was used intra-operatively to reduce the contrast load applied, 
and associated blood loss, both of which can affect renal function. Although available in the 
ITU/HDU setting, ‘reno-protective’ agents such as steroids, dopexamine and mannitol, were only 
given to a very small selection of patients, at the discretion of the attending Physician.  
In conclusion, this study adds further supporting biochemical evidence that EVAR in the 
treatment of AAA is safe from a renal perspective in mid to long term follow up. Furthermore, 
this preservation of renal function is independent of proximal fixation design. Although there 
would be insufficient patients to allow longer follow up periods, it seems likely that this trend of 
renal safety would continue.  
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Chapter 5. Serum NGAL and the management of AAA’s (Study 3) 
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5.1 Introduction 
As life expectancy within the population rises and increasing numbers of AAA’s are detected via 
screening programmes, or incidentally through scans for other pathology, the number of AAA’s 
referred for treatment seems set to rise. Traditionally these would have been repaired through an 
open approach with major abdominal surgery. Most vascular centres within the UK now follow 
an ‘EVAR first’ policy, meaning that all patients are considered primarily for EVAR over open 
surgery, unless there are specific contra-indications to EVAR. The endografts currently 
commercially available allow up to 66% of patients to be treated with EVAR
58
, although with 
further technological advancements, and the advent of widespread fenestrated EVAR (FEVAR) 
this is destined to increase. 
Acute renal failure following AAA repair is a serious complication, and has been observed in up 
to 10% of patients undergoing open AAA repair
139
 and EVAR
44
, and up to 39% in those having 
FEVAR
76, 140
. Acute renal failure is independently associated with significantly increased 
mortality and prolonged hospital stay following AAA repair, and up to 2% of these patients will 
require dialysis, with an associated mortality of up to 66%
141
. It is therefore vitally important to 
recognise renal failure promptly, to allow effective management, and hopefully reduce morbidity 
and mortality.  
Patients undergoing EVAR typically have a shorter hospital stay than that for open repair, and 
are sometimes discharged within 48 hours. Additionally in those vascular centres still learning 
EVAR, commencing a FEVAR service, or undertaking complex EVAR cases, there is a 
tendency to use greater quantities of radiological contrast agents peri-operatively, exposing the 
patients  to increased nephrotoxic risk. 
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Whilst serum creatinine (sCr) is a cheap and readily available marker of renal function for use in 
day to day clinical activities, it is widely recognised as a poor marker of renal function, with a 
marked reduction in GFR (up to 50%), and a stabilisation period of up to 72 hours needed, prior 
to biochemically detectable changes in sCr
136, 137
. 
As an acute phase marker of renal function, NGAL has been demonstrated to dramatically 
increase following renal injury from a variety of causes, particularly hypo-perfusion states and 
nephrotoxic insult. NGAL levels start to rise within two hours of the renal insult, rapidly 
peaking, and typically remain elevated for up to 48 hours, making NGAL an early and sensitive 
biochemical marker and predictor for acute renal injury
132, 142
. Due to the high risks associated 
with  renal failure in the AAA population, it is hoped that NGAL may serve as a useful adjunct 
in the management and detection of renal failure. 
Never previously assessed in the AAA population, the aims of this study are to test NGAL as a 
valid biochemical marker of renal function following AAA repair, and to investigate the 
relationship between NGAL and other variables (such as age, operation length, BMI), in the 
aneurysm population.  
 
 
 
 
 
 
99 
 
5.2 Patient and methods 
All patients consecutively listed for AAA repair in the Northern Vascular Centre (Newcastle, 
UK), for a 12 month period between August 2006 to 2007, were approached, given a full 
information sheet regarding the study (see Appendix D), and asked to sign a consent form (see 
Appendix F) for participation. The decision to treat individual patients was at the discretion of 
the Consultant in charge of that patient, and required an AAA diameter of greater than 5.5 cm, as 
well as a patient medically fit enough for surgery. The decision as to which method of AAA 
repair to use (EVAR or open repair), was decided at a multi-disciplinary meeting comprising 
several Vascular Surgeons and Consultant Radiologists, and was based on an ‘EVAR first 
policy’, whereby EVAR was the preferred method of treatment, assuming no specific contra-
indications.  
All patients were considered eligible for inclusion in the study, unless they suffered from chronic 
renal failure requiring dialysis, malignancy of any cause, acute or chronic inflammatory 
conditions (such as rheumatoid arthritis, inflammatory bowel disease), or infective AAA’s 
(mycotic aneurysms). These exclusion criteria were specifically chosen, since NGAL has been 
independently shown to be elevated in each of these conditions
126-128
, which could skew the 
results, making interpretation difficult. 
Once participation is the study was confirmed, patients were grouped according to repair type 
(EVAR or open repair), and then general demographic data (age, BMI, co-morbidity), as well as 
operative data (contrast load, operation length, type of operation), was collected for each patient. 
Patients were asked to provide blood samples for sCr and NGAL estimation pre-operatively, and 
then within 4, 24 and 48 hours of the procedure, with a final blood sample taken at standard 
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follow up, which was six weeks post procedure. All blood samples were collected by the primary 
investigator for the study. The timing of the blood samples was chosen specifically to correspond 
with any potential increases in NGAL following the procedure. All baseline sCr and NGAL 
levels were taken pre-operatively. The next blood test was taken at 4 hours following the start of 
the procedure, which was a convenient time for blood collection as all patients still had central 
access lines for blood collection, and any rise in NGAL due to renal insult (which would 
normally start after 2 hours), should have been readily detectable at that point. Bloods were then 
collected at 24 and 48 hours post-procedure to correspond to the routine blood tests that all 
patients underwent, so as to minimise invasive procedures on patients. Additionally, if there was 
any significant rise in NGAL, it would plateau at 24 hours, and start to decrease by 48 hours. 
Bloods were finally collected at 6 weeks follow up to confirm that all biochemical markers had 
returned to normal (pre-operative levels).  At each specific time point, any general or procedure 
related complications were recorded, and stored within a Microsoft Excel® database, constructed 
to store all the above information. 
Renal function was recorded using sCr was analysed on an Olympus 2700 multi channel analyser 
(Jaffé reaction based) using the manufacturers supplied reagents, providing a between batch 
imprecision of less than 2% for each analyte. Considered a routine blood test, analysis of sCr was 
performed by the Pathology Laboratory staff at the Northern Vascular Centre.  
NGAL levels were determined using the AntibodyShop NGAL Rapid ELISA test kit®. This 
involved a clotted blood sample being spun in a centrifuge for 10 minutes at 3000 rpm, and the 
resulting serum withdrawn and stored in a patient specific labelled well, at -80°C for later batch 
analysis. When analysis was to take place, the serum samples were diluted to 1/100, and a 50 µL 
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sample collected. This was then combined with 50 µL of HRP (horseradish peroxidise)-
conjugated monoclonal NGAL antibody (provided in the test kit), to produce a 100 µL substrate, 
which could be placed in the coated microwells of the 96 well ELISA test plates. These were 
incubated at room temperature on a shaking platform set at 200/minute for 30 minutes. The 
microwells were then emptied, washed with a pre-supplied diluted wash solution, before 100 µL 
of TMB (tetramethylbenzidine) substrate was added to each microwell, and the plates once again 
left to incubate at room temperature for 15 minutes. 100 µL of a supplied ‘stop solution’ was 
then added to each well to stop the reaction, and the 96 well plates were read at 450 nm in an 
ELISA microplate reader, using calibrated ELISA reader software incorporating curve fitting 
procedures to estimate NGAL. NGAL Rapid Calibrators were pre-supplied in the test kit, and 
used to form a calibration curve for the ELISA plate reader. Determination of NGAL was 
performed by the principal investigator under the direct guidance of Dr. R. Peaston, Senior 
Biochemist (Northern Vascular Centre, Newcastle, UK). 
Full ethical approval was sought and approved by Gateshead and South Tyneside Local Research 
Ethics Committee (reference: 07/H0901/42). 
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5.3 Data analysis 
All study information was anonymised and stored within a Microsoft Excel® (Microsoft Ltd.) 
spreadsheet. Relevant data was exported to Minitab 14® (Minitab Inc., PA, USA) for statistical 
analysis.  
Median values were used for continuous variables, and means for non-continuous variables. 
Renal data is represented by box and whisker plots, with boxes representing inter-quartile ranges, 
the intervening bar representing the median value, and whiskers representing the 90% range.  
For serial comparison of renal function two statistical methods were employed. The 1-sample 
Wilcoxon Test compared non-parametric continuous variables (such as within groups), and the 
Mann-Whitney U-Test compared 2 sample non-parametric variables (such as between groups). A 
Bonferroni correction factor was used for both when repeated analysis was made.  
The 2-sample t-test was employed for comparison of continuous variables. 
Linear regression was used when appropriate to assess the association between variables, with 
the relationship strength given by the Pearson correlation co-efficient, r.  
Results were statistically significant if p<0.05, with NS meaning not statistically significant. 
There is no clear consensus on the mean level of NGAL in a healthy population, as ranges vary 
widely, however most studies have reported mean levels of approximately 200ng/mL, with a 
standard deviation in the range of 100-150ng/mL. In those patients developing renal failure, the 
NGAL level would have to raise 200ng/mL to exceed the NGAL cut-off level of 400ng/mL, and 
103 
 
if powered to 80%, there would have to be between 6 or 10 patients within the renal failure 
group (for a SD of 100 or 150 ng/mL respectively), to achieve significance. 
All statistical methods employed were discussed with and approved by with Professor Matthews 
(Department of Mathematics and Statistics, University of Newcastle upon Tyne, Newcastle, UK) 
as part of the application and enrollment procedure for entry to the M.D. programme. 
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5.4 Results 
44 patients were enrolled in the study (23 EVAR, 21 open repair), with paired renal data at all 
time points, up to 48 hours available for all patients. Data was missing for 2 patients at six weeks 
because one had moved from the geographical area, and one patient died following EVAR due to 
myocardial infarction and subsequent left ventricular failure.  
Both groups were comparable and analogous with respect to demographics and co-morbidities 
(see Table 13), with the only statistically significant difference between the groups being the 
shorter operation length of EVAR vs open repair (210 vs 240 minutes respectively; p<0.05, 2-
sample t-test). 
All endografts were successfully deployed with no conversions to open repair during the study 
period. One EVAR patient re-presented to hospital within the first few weeks with bilateral 
buttock claudication, but patent internal iliac arteries, and is being kept under surveillance, with 
no current plans for re-intervention. A further EVAR patient presented with an occluded 
endograft limb, requiring femoral-femoral cross over grafting, and has subsequently made a full 
recovery with no further complications. There were no further cases of re-intervention needed in 
either study group. 
Within both study groups there were 3 cases of biochemically proven (raised Troponin-T), none 
of which needed emergency intervention (cardiac vessel stenting or thrombolysis). There were 4 
cases of post-operative acute renal dysfunction (sCr raised above baseline levels), in the open 
repair group, with no intra-operative precipitating factors identified. 3 of these patients 
responded to aggressive fluid replacement and management, and subsequently made a full 
recovery, with biochemical markers of renal function returning to pre-operative levels. One 
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patient required a short period of haemodialysis on the ITU for an acute renal failure developing 
at day 3, but made a full recovery, and return to normal renal function by the time of discharge 
from the hospital. There were two patients within the EVAR group who had a mild renal 
dysfunction (sCr >20% above baseline levels), persisting at 6 weeks, with unknown aetiology, 
and normal renal artery radiological imaging, which is being kept under surveillance.  
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Demographic EVAR (n=23) Open repair (n=21) 
Age (years) 
Median 
Range 
 
71 
57-85 
 
71 
28-82 
 
Co-morbidity: 
HTN 
MI/IHD 
Diabetes 
CVA 
CRF 
 
 
14 
8 
4 
1 
2 
 
 
12 
8 
2 
1 
2 
Smoking 
Ex smoker 
Current smoker 
 
9 
2 
 
5 
6 
Aneurysm size (mm) 
Median 
Range 
 
59 
55-80 
 
63 
55-93 
Operation length (mins) 
Median 
Range 
 
210 
120-330 
 
240 
150-660 
Contrast load (mls) 
Median 
Range 
 
180 
85-310 
 
N/A 
Pre-operative sCr (μmol/L) 
Median 
Range 
 
104 
72-154 
 
104 
58-211 
Pre-operative NGAL (ng/ml) 
Median 
Range 
 
129 
53-339 
 
150 
61-719 
 
Table 13: Group specific demographics 
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Correlation of NGAL with patient specific variables 
NGAL has previously been validated as a marker of renal function in patients undergoing cardiac 
and transplant surgery
132, 142
, but to date there is no understanding of its relationship to renal 
function in patients with AAA’s, or its relationship to potential confounding variables in patients 
having surgery for AAA’s.  
This study demonstrated a weak but statistically significant relationship between NGAL and sCr  
(r= +0.24, Pearson Correlation Co-efficient, p<0.05)(see Graph 8), and statistically significant 
relationships between operation length and NGAL at 4, 24 and 48 hours (r= +0.58, +0.33, -0.31 
respectively, Pearson Correlation Co-efficient, all p<0.05)(see Graph 11-13). 
There was no statistically significant relationship demonstrated between NGAL and AAA size or 
patient body mass index in the study (see Graph 9 & 10). 
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Graph 8: Correlation between NGAL and sCr (r= +0.24, p<0.05) 
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Graph 9: Correlation between pre-operative NGAL and AAA size (r= -0.13, p=NS) 
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Graph 10: Correlation between pre-operative NGAL and BMI (r= -0.20, p=NS) 
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Graph 11: Correlation between operation length and NGAL at 4 hours (r= +0.58, p<0.05) 
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NGAL at 24 hour time point (ng/ml)
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Graph 12: Correlation between operation length and NGAL at 24 hours (r= +0.33, p<0.05) 
NGAL at 48 hour time point (ng/ml)
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Graph 13: Correlation between operation length and NGAL at 48 hours (r= -0.31, p<0.05) 
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NGAL and renal function 
Throughout the study period, median sCr was comparable at each individual time point for the 
OR group (see Graph 14), with no statistically significant difference at any time point measured 
(p=NS,1-sample Wilcoxon test). There was however an increase of NGAL at both 4 and 24 
hours post procedure (see Graph 14), which showed statistical significance in comparison with 
other assay points in this group (p<0.05, 1-sample Wilcoxon test), and when compared to the 
corresponding 4 and 24 hour time points for the EVAR group (p<0.05, Mann Whitney U-Test). 
Within the OR group there were 3 instances of NGAL rising above the renal dysfunction 
predictor level (>400 ng/ml) at 4 hours. In one patient with NGAL at 942 ng/ml at 4 hours, the 
sCr rose from 144 μmol/L pre-operatively to 512 μmol/L at 48 hours. In another with NGAL at 
755 ng/ml at 4 hours, the sCr rose from 111 μmol/L pre-operatively to 371 μmol/L at 48 hours. 
In the third patient, NGAL rose to 530 ng/ml at 4 hours, but there was no significant rise in sCr, 
and NGAL levels subsequently fell. There was one instance of renal dysfunction, where pre-
operative sCr rose from 126 μmol/L to 217 μmol/L at 48 hours, and NGAL did not rise 
significantly until 24 hours post-operative, at which point it rose to 1051 ng/ml. There was one 
case of renal dysfunction, with sCr rising from 95 μmol/L to 176μmol/L at 48 hours, with no 
associated change in NGAL level. 
The EVAR group demonstrated a small rise in both sCr and NGAL at the 48 hour time point post 
procedure (see Graph 15), but this failed to gain statistical significance both within the EVAR 
group (p=NS, 1-sample Wilcoxon test) and when compared to the OR group (p=NS, Mann-
Whitney U-Test). 
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There were no instances of NGAL rising above the renal dysfunction predictor cut off level 
(>400 ng/ml) in the EVAR group at the 4 hour time point. Only two EVAR patients developed a 
mild renal dysfunction. For one their sCr rose from 120 umol/L pre-operatively to 157 umol/L at 
6 weeks, and for the other 150 umol/L to 181 umol/L respectively. Neither patient demonstrated 
an elevation in NGAL at 4 hours. At follow up CT angiography (6 weeks post operatively), both 
patients had patent renal arteries with good endograft position, and no evidence of renal infarcts. 
They are being managed conservatively with surveillance at present, and the aetiology of the 
renal dysfunction is not clear.  
Predictive value of NGAL in renal dysfunction 
When assessing the value of NGAL in predicting renal dysfunction in the AAA population, it is 
best to directly compare NGAL levels at all time points between those patients with and without 
renal dysfunction (see Graph 16). In this study, a total of 6 (13%) patients developed renal 
dysfunction (sCr rise >20% from baseline), following AAA repair. At the 4, 24 and 48 hour time 
point they have a much greater range of NGAL values compared to the normal renal function 
group (as demonstrated by the larger inter-quartile ranges on the box and whisker plots), 
indicating a possible trend towards renal dysfunction prediction. However median values were 
comparable between the two groups, with no statistically significant difference within groups (1-
sample Wilcoxon) or between groups (Mann-Whitney U-Test), at any time point.  
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Graph 14: NGAL and sCr at specific time points (OR group) 
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Graph 15: NGAL and sCr at specific time points (EVAR group) 
115 
 
 
 
Graph 16: Predictive value of NGAL in renal dysfunction, p=NS (1-sample Wilcoxon, Mann-
Whitney U-Test) 
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5.5 Discussion 
Renal failure following AAA repair of any type is an important entity, occurring in up to 10% of 
patients
44
, and is independently associated with significant morbidity and mortality
141
. Prompt 
recognition of renal failure is therefore necessary to allow treatment, and prevent adverse 
outcomes. 
Following renal injury from ischaemia or nephrotoxic agents, NGAL has been shown to up-
regulate in the kidney, and has emerged as a novel biochemical marker of acute renal failure
131
. 
It has been successfully used in both cardiac and transplant surgery, and as a predictor for 
contrast nephropathy in patients undergoing percutaneous coronary intervention 
132, 142
. To date it 
has not been assessed in the AAA population, and it is unknown if AAA specific factors will 
affect its use.  
Since NGAL occurs naturally in complex with matrix metalloproteinase-9 (MMP-9), a 
proteinase associated with AAA development and rupture
143
, there was concern that the AAA 
population may have naturally occurring higher levels, making NGAL less useful as a marker of 
renal function. This study assessed the relationship of NGAL to AAA size, and patient BMI, and 
found no statistically significant correlation. This was most likely because the majority of NGAL 
occurs as a monomer in neutrophils, with only a small percentage in complex with MMP-9, 
resulting in no significantly elevated levels in the AAA population, and because NGAL, unlike 
sCr, is not directly influenced by body muscle mass or size.  
NGAL correlated positively and significantly with operation length at 4 and 24 hours post 
procedure, indicating a positive relationship between renal confounding factors and NGAL in the 
AAA population. Additionally, when assessing the relationship between NGAL and sCr in the 
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AAA population, there was a statistically significant, albeit weak correlation found. We suggest 
that this correlation was weak, because unlike other biochemical renal function markers, which 
correlate linearly with sCr, NGAL rises exponentially with renal dysfunction, making individual 
predictions of NGAL levels from sCr difficult. Additionally, since sCr is a relatively poor marker 
of renal function, requiring significant changes in GFR prior to alteration in levels, it may be that 
any subtle change in GFR, detected by small but not clinically significant rises in NGAL, is just 
not represented by the associated sCr levels, resulting in a weak correlation.  
This study demonstrated a small but statistically significant rise in NGAL at 4 and 24 hours 
following open AAA repair, with no corresponding similar change in the EVAR group. It was 
not entirely clear why there was no similar rise in the EVAR group, but it was felt that this 
difference occurred due to the greater physical stresses placed on the body and kidneys during 
the open AAA repair. Of particular note, no patients in the EVAR group suffered inadvertent 
cannulation of the renal arteries, or developed contrast nephropathy, whereas all open AAA 
patients underwent dissection of the aortic neck and manipulation of the tissues surrounding the 
renal arteries to enable safe clamp application. This could potentially have exposed the open 
AAA patients to small, but clinically insignificant changes in renal function, accounting for the 
change in NGAL. It is believed that the median sCr did not subsequently rise in the open AAA 
group because the rise in median NGAL observed was below the renal dysfunction cut off level 
(>400ng/L), and thus represents only a mild or sub clinical renal dysfunction, unable to be 
detected by sCr. Of the 4 patients that developed renal dysfunction in the OR group, 
demonstrated by a rise in sCr at 48 hours, 2 were predicted by a rise in NGAL at 4 hours well 
above the cut off level. Of the remaining two, one never experienced an NGAL rise, and for the 
other the rise occurred at 24 hours post-procedure. 
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In the EVAR group there was a small but statistically insignificant rise in NGAL at 48 hours 
post-procedure, and this was not associated with any significant rises in sCr. It is possible this 
occurred because EVAR patients were all managed in the high dependency unit (HDU) post-
procedure for at least 24 hours, enabling accurate control of hydration. They were generally 
moved to standard surgical wards between 24 and 48 hours, with cessation of intravenous fluids 
and commencement of oral intake. It is possible that this change in fluid intake prompted a mild 
dehydration and renal insult, detected by NGAL, although not sufficient to cause a frank renal 
failure and rise in sCr. The open AAA group generally stayed for at least 48 hours in the 
intensive care unit (ITU), avoiding this potential complication. Another possible explanation is 
the use of CT angiography to check the endograft (correct position, absence of endoleaks), prior 
to discharge. This typically occurred at 48 hours post-procedure, and involved a further bolus of 
contrast agent. It is suggested that since this second renal insult was insufficient to precipitate 
renal failure, that this is the reason the rise in NGAL was small and not statistically significant. 
Of the two patients that developed mild renal dysfunction (not requiring renal replacement 
therapy) in the EVAR group, there was no rise in NGAL at any time point. Their renal 
dysfunction is unchanged and persists at 6 weeks post procedure, with aetiology unknown (no 
renal infarcts or stent migration proximally detected on follow up CT).  
When those patients with renal dysfunction are compared directly to those without renal 
dysfunction (see Graph 16), a clear trend is demonstrated. Those patients who develop renal 
dysfunction have a much greater range of NGAL values at the 4 and 24 hour time point, 
indicating a potential trend towards the prediction of renal dysfunction in the AAA population. 
Although median values were comparable between groups and time points, with no statistically 
significant differences detected, the numbers of patients with real dysfunction were too small for 
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accurate analysis. This demonstrates one of the limitations of this study. When used in other 
clinical scenarios, such as renal transplantation and percutaneous coronary intervention, there are 
generally much higher rates of clinically significant renal dysfunction recorded (up to 40% of 
patients), making any correlation of NGAL with renal function easier. In this study only 13% 
(6/44) of all patients developed renal dysfunction. These findings do however highlight a 
potential for prediction which should be assessed with greater patient numbers. To fully assess 
the predictive value of NGAL in the AAA population would require greater patient numbers 
(from several study years), or the use of a multi-centre collaboration.  
The addition of a control group may have been of value to this study. A group with no history of 
AAA disease, but undergoing either major abdominal surgery or angiography with contrast 
agents would have added validity to the use of NGAL in AAA patients, by removing the 
potential confounding factor of AAA disease.  
Additionally it would be of value in any future studies to use a more accurate measurement or 
estimation of GFR to confer greater validity on any change in NGAL found. This study used sCr 
as it was cheap, readily available and was simple to analyse. The most obvious and simple 
marker to use in its place for greater accuracy would be Cystatin C to allow more accurate GFR 
estimation. 
Sampling of blood for NGAL analysis was taken as close as possible to the defined time points 
both peri and post-operatively, but it is acknowledged that there will be some sampling error 
here. The commencement of renal insult was defined as the introduction of the first guide wire 
intra-vascularly through the AAA for EVAR patients, and the commencement of retro-peritoneal 
dissection of the AAA neck for OR patients. 
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Whilst there is no formal renal protection policy within this centre for patients undergoing AAA 
repair, much was done to prevent renal dysfunction. All patients underwent urinary 
catheterisation and central venous pressure monitoring to enable optimisation of fluid 
management peri-deployment of the endograft, and in the immediate post care setting of HDU or 
ITU. If clinically indicated, then ‘reno-protective’ agents, steroids, mannitol, dopexamine were 
administered, but were not done so on a routine basis, and were at the discretion of the 
Consultant Physician in charge of ITU/HDU. No participants in this study required ‘reno-
protective’ agents as part of their treatment. 
Instead of predicting renal failure, several recent studies have investigated the prevention of renal 
dysfunction. The Department of Vascular Surgery at the University of Cologne, has investigated 
the use of statins given pre-operatively in the protection of SR-EVAR patients from renal 
dysfunction. They demonstrated a post-operative reduction in CrC from 74.1 ml/min to 68.0 
ml/min (p<0.001), in patients undergoing SR-EVAR without statin cover, and no clinical or 
statistically significant deterioration in those that were on statins
144
. Since all patients with 
vascular disease in the UK are routinely prescribed statins (unless contra-indicated), their 
findings appear to be limited, other than to emphasise the importance of statins in vascular 
patients.  Perhaps of more importance to UK Vascular Centres is the reduction in the use of 
contrast agents used during EVAR. The Munich Department of Vascular Surgery report on the 
use of real time contrast enhanced ultra-sound in the deployment of EVAR, as an alternative to 
angiography or CT. They successfully visualised the proximal landing zone in 82.4% of patients, 
and the distal landing zone in 89.3%. They report a statistically significantly lower volume of 
contrast used, compared to conventional angiography
145
. Although a novel suggestion, this 
would require significant re-training of surgeons, investment in expensive equipment, and access 
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to traditional angiography if visualisation of the deployment was not possible. As an evolving 
technology, it may yet be of value.  
Although essentially a study of negative findings, there are still important conclusions to be 
made. If NGAL had been inappropriately elevated at all study points (because NGAL is a 
modulator of MMP-9), then it would have demonstrated the failure of NGAL as a renal function 
marker in the AAA population; and this was not the case. Due to insufficient numbers of patients 
with renal dysfunction following AAA repair, it was not possible to fully assess the role of 
NGAL in this clinical scenario, although a weak (but statistically significant) relationship 
between NGAL and renal function in the AAA population was demonstrated.  
It is still believed that further research into the role of NGAL in the management of AAA’s is of 
value. There is a relatively high rate of renal failure following AAA repair of all types, and 
decrease in renal function post operatively is independently associated with decreased 5 year 
survival following surgery
146
 and increased morbidity
141
. There is only limited benefit that can be 
achieved by manipulation of intra-operative renal confounding factors, and only so much pre-
operative patient optimisation to reduce this risk of renal failure (aggressive pre-hydration). An 
early renal marker, which could be sampled peri-operatively with no added hassle, potentially 
detecting renal failure within hours of the renal insult would be of great benefit. It would allow 
the use of ‘reno-protective’ agents pre-emptively, and on a targeted basis to reduce these risks.  
Perhaps the most obvious direction for further research involving NGAL and AAA’s would be in 
the management of FEVAR. With much higher rates of acute renal dysfunction reported (up to 
39%)
76, 140, 147
, the importance of early detection through a simple to use biochemical marker 
could not be more paramount. 
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As life expectancy improves and screening for AAA’s becomes commonplace, there will be 
increasing numbers of patients referred for the treatment of their AAA’s. Traditionally this was 
performed by open surgical endo-aneurysmorrhaphy, and placed considerable stresses on the 
patient, with considerable morbidity and mortality risks. As such only patients deemed 
‘medically fit’ for surgery were considered. The need for a treatment option with lower 
associated risks, and suitable for ‘medically unfit’ patients, was great.  
Since Parodi first described EVAR some 20 years ago
15
, there have been considerable 
developments. Endografts have evolved from simple tube stents with single point fixation, to 
complex modular devices with trans-renal (SR) fixation. This has improved eligibility of AAA’s 
to over 60% of the AAA population
58
, and this figure seems set to rise with further endograft 
development, and the advent of cheap and accessible fenestrated endografts (FEVAR).  
A key concern with SR EVAR was the impact on renal function. Several studies reported 
comparable rates of renal infarction following SR-EVAR compared to IR-EVAR 
50, 133
, and 
similar rates of renal dysfunction following both methods in the immediate to mid-term follow 
up
44, 51-56, 134
. To date evidence for renal safety following SR-EVAR in the long term is lacking, 
but needed to determine SR EVAR safety.  
Renal function is typically measured in the clinical setting using sCr and the Cockroft-Gault 
derived CrC to estimate GFR. This is easy to perform, cheap and readily available in most 
centres. sCr metabolism however can be directly influenced by muscle mass, sex and dietary 
intake of proteins. Additionally, sCr and CrC are poor renal markers, requiring significant 
changes in GFR prior to any detectable alteration in their levels. 
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Cystatin C, a low molecular weight protein and proteinase inhibitor, has been validated as an 
effective and accurate measurement of renal function, compared to gold standard clearance 
methods
120
. Unlike sCr it is not affected by sex, muscle mass or dietary intake, and can be readily 
and economically quantified with a commercially available PETIA kit. Whilst it has 
demonstrated the renal safety of SR EVAR in the short term
135
, it has not been used in mid to 
long term follow up of SR EVAR patients, and is hoped that it will confirm the findings already 
shown by sCr and CrC. 
Additionally there has been considerable interest recently in NGAL as a novel marker of acute 
renal dysfunction. NGAL is a member of the lipocalin family of proteins, and although its role is 
not fully understood, it is believed to play a role in stress response. Studies have demonstrated 
considerable rises in NGAL shortly following renal insult during cardiac and transplant surgery, 
and following nephrotoxic injury
132, 142
.  With the increasing use of EVAR and future potential 
for FEVAR, it is of vital importance to have a reliable indicator and predictor of potential renal 
dysfunction. This would enable rapid treatment of any predicted renal failure, reducing 
associated morbidity and mortality. 
The aims of this thesis include: 
 To assess long term renal safety following EVAR, in particular SR-EVAR (Study 1) 
 To assess mid to long term renal function following EVAR using Cystatin C (Study 2) 
 To evaluate the role of NGAL in the management of AAA’s (Study 3) 
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Study 1 was a retrospective and prospective analysis of all patients having undergone EVAR 
(either IR or SR) at the Northern Vascular Centre between 1996 and 2001.  
Using sCr and the calculated CrC, the study confirmed there was no statistically significant 
deterioration in renal function in either group up to 84 months post deployment. Paired renal data 
was available up to 120 months, and demonstrated a lack of difference in renal function to this 
time point, however there were insufficient patient numbers for statistical analysis. 
Other recent studies have confirmed these findings, demonstrating the renal safety of EVAR in 
the mid to long term. The recently reported long term follow up from the EVAR trials found no 
statistically significant difference in rate of change in eGFR between OR and EVAR with a mean 
follow up of 3.6 years, and 1194 patients
138
. Additionally, this study confirms the findings of and 
adds to the body of work already performed demonstrating long term renal safety following 
EVAR (utilising sCr and CrC)
35, 44, 49, 50, 54-57
. 
The strengths of this study were long follow up periods, with a mean of 40.5 months, and paired 
renal data with sufficient numbers for statistical analysis up to 84 months. Further, all procedures 
were performed in a single centre, by a select group of surgeons/radiologists, using only one type 
of SR device, in contrast to other studies.  
Principal weaknesses of the study include the use of outdated IR devices (the Vanguard® device 
is no longer commercially available), and the lack of long term renal data following OR (as a 
potential control group) from the same time period, patients having OR are not routinely 
followed in clinics long term (unless enrolled in specific trials). Additionally, due to the 
relatively small number of patients during the study period, longer follow up will be difficult to 
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perform. AAA patients have co-morbidities which generally preclude long term survival 
following AAA repair.  
 
Study 2 was a prospective analysis of a previously selected group of patients from a previous 
study, having undergone EVAR or OR, using Cystatin C as a marker of renal function. Cystatin 
C was used to ensure that there was no renal dysfunction mid to long term following EVAR, that 
sCr was unable to detect due to lack of sensitivity. Paired renal data was available up to 4 years 
post AAA treatment, and confirmed the renal safety of SR-EVAR compared to open AAA 
repair. Validation of Cystatin C as an effective renal marker in AAA patients was confirmed at 
midterm follow up.  
This study validated the recently published finding from the EVAR trial
138
 midterm data. Using 
estimated GFR the EVAR Trial found no significant difference in renal function between OR 
and EVAR with a mean follow up of 3.6 years. Using Cystatin C, an acknowledged and accurate 
marker of renal dysfunction and  GFR, this study demonstrated no significant difference in renal 
function up to 4 years between OR and EVAR, confirming the mid to long term renal safety of 
EVAR (SR EVAR in this respect as all endografts were SR type). 
The strength of this study include long follow up periods using Cystatin C as a marker of renal 
function in AAA patients, and the use of a more sensitive renal function marker (GFR marker), 
to truly determine the renal safety of EVAR.  
The principal weaknesses are the small number of patients enrolled in the initial trial period. This 
has enabled follow up to 4 years, however at this point there were only 17 patients in each arm of 
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the study, the minimum required for successful statistical analysis, and as such further long term 
follow up seems unlikely.  Further work could involve taking a sample of IR, SR and OR 
patients from any time point following surgery, and analysing renal function using Cystatin C. 
There would be no paired renal data, but if demographics between the groups were similar, 
comparison of renal function could be made. Additionally, it would have been more accurate to 
have an IR control group as part of the original study, since SR EVAR and OR are two different 
technologies. For true comparison it would be necessary to compare different endograft types 
directly, ie. those with SR and IR fixation using Cystatin C. 
 
Study 3 was a prospective analysis of patients undergoing EVAR or open AAA repair using 
NGAL as a marker and predictor of acute renal dysfunction post-operatively. Whilst there was a 
small but significant rise in the first few hours following open AAA repair, this did not result in a 
subsequent rise in sCr and renal dysfunction. There was no statistically significant rise of NGAL 
in the EVAR group, and no subsequent statistically significant rise in sCr. These results were 
primarily felt to reflect the greater stresses and impact of open surgery on the kidneys, and the 
resultant rise in sCr lacking since the NGAL level did not rise above 400 ng/L (previously shown 
as the renal dysfunction cut off value). The EVAR group had relatively short operation durations, 
small contrast loads, and were well hydrated, and no EVAR patients developed overt contrast 
nephropathy as a result.  
Whilst NGAL has been validated for use in other procedures (coronary catheterisation, 
transplant), its role as a modulator of MMP-9 (associated with the development of AAA’s) has 
clouded its use in the aneurysm population. NGAL was demonstrated to correlate weakly, but 
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significantly with sCr as a marker of renal function in AAA patients. It did not significantly 
correlate with AAA size, or patient BMI, confirming that it may yet have a role in AAA 
management. 
In 3 of the 6 patients who developed renal dysfunction , NGAL levels rose within the first 24 
hours, indicating a potential predictive role for NGAL. In 2 patients there was no rise in NGAL, 
and in the last patient there was a delayed rise in NGAL. The number of patients within the study 
developing renal dysfunction following AAA repair 13% (6/44), was insufficient to make 
accurate statistical analysis for the role of NGAL as a predictor of potential renal dysfunction, 
although there was a trend identified of wider ranges of NGAL levels in the renal dysfunction 
patients at the 4, 24 and 48 hour time points post-surgery. 
To achieve appropriate numbers of AAA patients developing renal failure and to allow the 
assessment of NGAL as a predictor of renal function, the study would have to be a longer 
duration, or potentially multi-centre. In any further analysis of NGAL it would be helpful to 
include a control group, of patients undergoing major abdominal surgery, to allow direct 
comparison with OR, without vascular disease as a potential confounding factor.  
 
In conclusion, this research has demonstrated the continued renal safety of EVAR in the mid to 
long term follow up, regardless of proximal fixation type.   
Despite correlating with routine biochemical renal function markers in AAA patients, the role of 
NGAL in the management of AAA patients needs further exploration and assessment. 
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Appendix A: Cystatin C patient information sheet 
Patient Information sheet 
The long term impact of trans-renal aortic endograft fixation for abdominal aortic 
aneurysm repair on renal function 
(Cystatin C Cohort) 
The study 
You are invited to take part in a research study to evaluate the long term effect of placing an 
aortic implant (artificial blood vessel), for the treatment of abdominal aortic aneurysms (dilated 
aortic blood vessel), across the blood supply of the kidneys. Before you decide it is important to 
understand why the research is being done, and what it will involve. Please take time to read the 
information sheet carefully, and talk to others about the study if you wish. If the information 
sheet is not clear, or if you require more information, please feel free to ask questions. Take time 
to decide whether to participate.  
Thankyou for reading this.  
Background 
Over the last fifteen years medical advances have enabled some patients to undergo key-hole 
repair of abdominal aortic aneurysms (dilated aortic blood vessel). This means faster recovery 
and less invasive surgery for eligible patients compared to traditional surgical repair (requiring a 
large abdominal operation). Whilst usually performed in specialist vascular surgery centres, this 
procedure is gaining popularity nationwide. The manufacturers have constantly developed the 
implants, so that the latest implants have a portion that covers the blood supply of the kidneys. 
This is in contrast to the earlier devices which were fixed in place below this blood supply. The 
reason for this change is to allow the implant better attachment, and to prevent it slipping after 
the operation. 
A lot is now known about the benefits and disadvantages that can occur with both types of 
implants. Research studies from around the world have shown no disadvantage to covering the 
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blood supply of the kidneys in the first few years after the operation, but we do not know the 
long term effect, if any, of covering the blood supply.  
There is a theoretical risk of reducing the blood supply to the kidneys by covering the blood 
vessels, thus preventing their normal function. 
You will have had either the implant covering the kidneys’ blood supply or the traditional 
surgical repair (large abdominal operation). 
Purpose of the study 
This study will allow us to compare the effect of the different surgical options on the long term 
function of the kidneys. It will allow us to compare the effect of covering the blood supply with 
an implant versus not covering the blood supply as happens in the traditional surgical repair. 
It will allow us to create more accurate guidelines for monitoring patients with these implants 
after the operation, and help confirm the safe use of such implants.  
Do I have to take part? 
When you had the operation you consented to enrolment in the Cystatin C trail, which was an 
earlier version of this trial, and were followed closely for the first two years after the operation 
with routine and experimental blood tests for renal function. The analysis of this data to date has 
helped to confirm the safety of this type of operation.  
We hope to re-recruit each of the 60 patients that were part of the Cystatin C trial so that we can 
take a single blood test in the out-patients department, and compare this to the previous blood 
test results from yourself and other patients that are held on our database. 
It is your decision to take part or not. 
If you are happy to participate, you will be given a copy of this information sheet, and asked to 
sign a consent form. 
You are free to withdraw from the study at any point, and doing so will not affect your 
continuing standard of care. 
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What will I have to do? 
Once you agree to participate we will need to take a sample of blood. This is in addition to the 
routine blood tests that you have on a yearly basis. This will take place in the out-patient clinic, 
when you will be attending for your yearly follow up. From this sample of blood we will be able 
to estimate how well the kidneys are working, and compare this to previous samples from 
yourself and other patients (following the operation), that are held within the database. This is 
the only participation we require of you, and so does not require further attendance at the 
hospital. The only difference to your routine clinical follow-up is the need for an extra blood test. 
If an unexpected abnormal result is detected in the blood test then the Consultant in charge of 
your care will be informed, and appropriate action taken. 
The next time you are seen will be in one years time for your routine follow up.  
Confidentiality 
Patients enrolled in this study will be treated confidentially to the same level as standard NHS 
practice. All data received will be stored in a database on a  password controlled hospital 
computer, and only those doctors contributing to the study will have access. 
All data collected will be fully anonymised prior to any presentations at medical conferences or 
publication in medical journals. All data held within the database will be anonymised at the first 
available opportunity. 
Results of the study 
The results will be presented at medical conferences, and in medical journals. 
The research will also contribute to the completion of an MD for Mr. Tim Parkinson (principal 
researcher).  
Funding 
The research is funded by the Northern Vascular Research Trust. 
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Appendix B: Eurostar Cohort patient information sheet 
Patient Information sheet 
The long term impact of trans-renal aortic endograft fixation for abdominal aortic 
aneurysm repair on renal function 
(EUROSTAR Cohort) 
The study 
You are invited to take part in a research study to evaluate the long term effect of placing an 
aortic implant (artificial blood vessel), for the treatment of abdominal aortic aneurysms (dilated 
aortic blood vessel), across the blood supply of the kidneys. Before you decide it is important to 
understand why the research is being done, and what it will involve. Please take time to read the 
information sheet carefully, and talk to others about the study if you wish. If the information 
sheet is not clear, or if you require more information, please feel free to ask questions. Take time 
to decide whether to participate.  
Thankyou for reading this.  
Background 
Over the last fifteen years medical advances have enabled some patients to undergo key-hole 
repair of abdominal aortic aneurysms (dilated aortic blood vessel). This means faster recovery 
and less invasive surgery for eligible patients compared to traditional surgical repair (requiring a 
large abdominal operation). Whilst usually performed in specialist vascular surgery centres, this 
procedure is gaining popularity nationwide. The manufacturers have constantly developed the 
implants, so that the latest implants have a portion that covers the blood supply of the kidneys. 
This is in contrast to the earlier devices which were fixed in place below this blood supply. The 
reason for this change is to allow the implant better attachment, and to prevent it slipping after 
the operation. 
A lot is now known about the benefits and disadvantages that can occur with both types of 
implants. Research studies from around the world have shown no disadvantage to covering the 
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blood supply of the kidneys in the first few years after the operation, but we do not know the 
long term effect, if any, of covering the blood supply.  
There is a theoretical risk of reducing the blood supply to the kidneys by covering the blood 
vessels, thus preventing their normal function. 
You will have had either of the implant types mentioned above in your original operation. 
Purpose of the study 
This study will allow us to compare the effect of the different surgical options on the long term 
function of the kidneys. It will allow us to compare the effect of covering the blood supply 
versus not covering it when using the different types of implant.  
It will allow us to create more accurate guidelines for monitoring patients with these implants 
after the operation, and help confirm the safe use of such implants. 
Do I have to take part? 
When you had the operation you consented to enrolment in the EUROSTAR database, and were 
followed closely for the first two years after the operation with blood tests and scans, and then 
yearly thereafter with scans.  This analysis of this data to date has helped to confirm the safety of 
this type of operation.  
We hope to re-recruit each of the 240 patients that are part of the EUROSTAR database so that 
we can take a single blood test in the out-patients department, and compare this to the previous 
blood test results that are held on the database. 
It is your decision to take part or not. 
If you are happy to participate, you will be given a copy of this information sheet, and asked to 
sign a consent form. 
You are free to withdraw from the study at any point, and doing so will not affect your 
continuing standard of care. 
What will I have to do? 
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Once you agree to participate we will need to take a sample of blood. This will take place in the 
out-patient clinic, when you will be attending for your yearly follow up. From this sample of 
blood we will be able to estimate how well the kidneys are working, and compare this to 
previous samples from yourself and other patients (following the operation), that are held within 
the database. This is the only participation we require of you, and so does not require further 
attendance at the hospital. The only difference to your routine follow-up is the need for a blood 
test. 
If an unexpected abnormal result is detected in the blood test then the Consultant in charge of 
your care will be informed, and appropriate action taken. 
The next time you are seen will be in one years time for your routine follow up.  
The process of taking blood will add approximately 10 minutes to your clinic attendance. 
Confidentiality 
Patients enrolled in this study will be treated confidentially to the same level as standard NHS 
practice. All data received will be stored in a database on a  password controlled hospital 
computer, and only those doctors contributing to the study will have access. 
All data collected will be fully anonymised prior to any presentations at medical conferences or 
publication in medical journals. All data held within the database will be anonymised at the first 
available opportunity. 
Results of the study 
The results will be presented at medical conferences, and in medical journals. 
The research will also contribute to the completion of an MD for Mr. Tim Parkinson (principal 
researcher).  
Funding 
The research is funded by the Northern Vascular Research Trust. 
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Appendix C: EVAR Trial Cohort patient information sheet 
 
Patient Information sheet 
The long term impact of trans-renal aortic endograft fixation for abdominal aortic 
aneurysm repair on renal function 
(EVAR Cohort) 
The study 
You are invited to take part in a research study to evaluate the long term effect of placing an 
aortic implant (artificial blood vessel), for the treatment of abdominal aortic aneurysms (dilated 
aortic blood vessel), across the blood supply of the kidneys. Before you decide it is important to 
understand why the research is being done, and what it will involve. Please take time to read the 
information sheet carefully, and talk to others about the study if you wish. If the information 
sheet is not clear, or if you require more information, please feel free to ask questions. Take time 
to decide whether to participate.  
Thankyou for reading this.  
Background 
Over the last fifteen years medical advances have enabled some patients to undergo key-hole 
repair of abdominal aortic aneurysms (dilated aortic blood vessel). This means faster recovery 
and less invasive surgery for eligible patients compared to traditional surgical repair (requiring a 
large abdominal operation). Whilst usually performed in specialist vascular surgery centres, this 
procedure is gaining popularity nationwide. The manufacturers have constantly developed the 
implants, so that the latest implants have a portion that covers the blood supply of the kidneys. 
This is in contrast to the earlier devices which were fixed in place below this blood supply. The 
reason for this change is to allow the implant better attachment, and to prevent it slipping after 
the operation. 
A lot is now known about the benefits and disadvantages that can occur with both types of 
implants. Research studies from around the world have shown no disadvantage to covering the 
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blood supply of the kidneys in the first few years after the operation, but we do not know the 
long term effect, if any, of covering the blood supply.  
There is a theoretical risk of reducing the blood supply to the kidneys by covering the blood 
vessels, thus preventing their normal function. 
As part of the EVAR trial you will have had either the key-hole or traditional surgical repair 
(requiring a large abdominal operation).  
Purpose of the study 
This study will allow us to compare the effect of the different surgical options on the long term 
function of the kidneys. It will allow us to compare the effect of covering the blood supply with 
the implant in key-hole repair versus not covering it when using the traditional surgical repair. 
It will allow us to create more accurate guidelines for monitoring patients with these implants 
after the operation, and help confirm the safe use of such implants. 
Do I have to take part? 
When you had either operation you consented to enrolment in the EVAR trial, and were followed 
closely for the first two years after the operation  and then yearly thereafter with blood tests and 
scans held on a database. The analysis of this data to date has helped to confirm the safety of this 
type of operation.  
We hope to re-recruit each of the 140 patients that were part of the EVAR trial so that we can 
obtain consent to use the results of the scans and blood tests to date to fully evaluate the different 
operations. 
It is your decision to take part or not. 
If you are happy to participate, you will be given a copy of this information sheet, and asked to 
sign a consent form. 
You are free to withdraw from the study at any point, and doing so will not affect your 
continuing standard of care. 
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What will I have to do? 
The only requirement we have is the signing of the consent form to enable us to access the 
previous and current scan and blood test results. There is no other difference to your routine 
follow-up. 
If an unexpected abnormal result is detected in either the scan or blood tests then the Consultant 
in charge of your care will be informed, and appropriate action taken. 
The next time you are seen will be in one years time for your routine follow up.  
Confidentiality 
Patients enrolled in this study will be treated confidentially to the same level as standard NHS 
practice. All data received will be stored on a database in a password controlled hospital 
computer, and only those doctors contributing to the study will have access. 
All data collected will be fully anonymised prior to any presentations at medical conferences or 
publication in medical journals.  
All data held within the database will be anonymised at the first available opportunity. 
Results of the study 
The results will be presented at medical conferences, and in medical journals. 
The research will also contribute to the completion of an MD for Mr. Tim Parkinson (principal 
researcher).  
Funding 
The research is funded by the Northern Vascular Research Trust. 
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Appendix D: Vascular patients patient information sheet 
Patient Information sheet 
VASCULAR PATIENTS 
Neutrophil gelatinase associated lipocalin (NGAL) and the management of renal function 
following abdominal aortic aneurysm (AAA) repair 
The study 
As a patient with an abdominal aortic aneurysm/AAA (dilated aortic blood vessel), you are 
invited to take part in a research study to evaluate a new type of blood test for kidney function 
following repair of the AAA. 
This study will involve patients with AAA’s, having various forms of surgery, and patients who 
do not have AAA’s, ie. Colorectal (bowel) operations, who will be used for comparison. 
Before you decide it is important to understand why the research is being done, and what it will 
involve. Please take time to read the information sheet carefully, and talk to others about the 
study if you wish. If the information sheet is not clear, or if you require more information, please 
feel free to ask questions. Take time to decide whether to participate.  
Thank you for reading this.  
Background 
Over the last fifteen years medical advances have enabled some patients to undergo key-hole 
repair of abdominal aortic aneurysms (dilated aortic blood vessel). This means faster recovery 
and less invasive surgery for eligible patients compared to traditional surgical repair (requiring a 
large abdominal operation). Whilst usually performed in specialist vascular surgery centres, this 
procedure is gaining popularity nationwide. The manufacturers have constantly developed the 
implants, so that the latest implants have a portion that covers the blood supply of the kidneys. 
This is in contrast to the earlier devices which were fixed in place below this blood supply. The 
reason for this change is to allow the implant better attachment, and to prevent it slipping after 
the operation. 
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A lot is now known about the benefits and disadvantages that can occur with both types of 
implants. Research studies from around the world have shown no disadvantage to covering the 
blood supply of the kidneys in the first few years following implantation of the device.  
However a small number of people experience a decrease in kidney function immediately 
following this procedure, and for the vast majority this requires no treatment other than a 
intravenous infusion of water (a drip), for a day or two.  
It is however important to detect this decrease in kidney function, and to act on it as appropriate. 
Purpose of the study 
Our standard blood tests (which are used globally), can be slow to demonstrate decreases in 
kidney function, occasionally only altering after a few days, by which time most people having 
key hole repair will have gone home. 
This study will allow us to analyse the efficiency of a new blood test (NGAL) at detecting 
kidney function following these operations, and compare it to the standard blood tests used at 
present. 
It will also allow us to compare the effect of covering the blood supply with the implant in key-
hole repair versus not covering it when using the traditional surgical repair. 
It will allow us to create more accurate guidelines for monitoring patients with these implants 
after the operation, and help confirm the safe use of such implants. 
Do I have to take part? 
We hope to recruit about 50 patients into this study, some having treatment for AAA’s, and some 
undergoing Colorectal (bowel) operations (who do not have aneurysms). 
The Consultants responsible for your care are aware of the study, and happy for your 
participation, although it is your decision as to whether to take part. 
If you are happy to participate, you will be given a copy of this information sheet, and asked to 
sign a consent form. 
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You are free to withdraw from the study at any point, and doing so will not affect your 
continuing standard of care. 
What will I have to do? 
The study requires 5 blood tests from you. One before the operation, and then at 6, 24 and 48 
hours following the procedure. There will be one last blood test when you return for your routine 
out-patient appointment.  
No additional attendance above the routine practice will be required. 
Blood tests are routinely taken as part of normal care pre-procedure, and at 24 and 48 hours, 
during which the research sample can be taken.  
This means you will only need to provide 2 blood samples above and beyond your routine care 
and management. 
Confidentiality 
Patients enrolled in this study will be treated confidentially to the same level as standard NHS 
practice. All data received will be stored on a database in a password controlled hospital 
computer, and only those doctors contributing to the study will have access. 
All data collected will be fully anonymised prior to any presentations at medical conferences or 
publication in medical journals.  
All data held within the database will be anonymised at the first available opportunity. 
Results of the study 
The results will be presented at medical conferences, and in medical journals. 
The research will also contribute to the completion of an MD for Mr. Tim Parkinson (principal 
researcher).  
Funding 
The research is funded by the Northern Vascular Research Trust. 
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Appendix E: Renal function & Cystatin C consent form 
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Appendix F: NGAL study consent form 
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Appendix G: Blood sample bottle labels 
 
 
 
 
Labels created for the management and storage of blood samples. 
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Appendix H: Study 1 RAW data 
 
 
IR fixation time interval specific sCr (umol/L) and CrC (ml/min) levels 
 
48 months 60 months 72 months 84 
months 
96 
months 
108 
months 
120 
months 
sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC 
104 64.5 * * * * 114 56.3 * * * * 102 60.2 
84 73.2 * * * * * * * * * * 99 56.4 
* * 138 35.4 132 36.4 128 36.8 142 32.6 * * * * 
110 59.1 * * 119 53.0 * * * * * * 125 47.4 
* * * * 152 57.8 177 49.0 * * 168 50.2 * * 
* * * * * * * * * * * * * * 
* * * * 91 57.0 90 56.8 * * * * 88 55.4 
* * * * * * * * * * * * * * 
* * * * 162 48.9 142 54.9 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 121 47.9 130 46.3 155 36.0 160 34.2 149 36.0 
* * * * 89 65.7 70 82.4 * * * * * * 
* * * * * * * * * * * * * * 
95 64.2 105 53.0 * * 125 46.7 * * 126 44.9 133 41.8 
128 48.3 * * * * * * * * * * * * 
92 48.4 83 52.6 * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * 106 52.5 * * * * * * * * * * 
* * 104 74.7 95 80.7 * * * * * * * * 
* * * * * * * * * * * * * * 
* * 107 69.8 * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
114 39.6 108 41.2 102 43.0 105 53.0 * * * * * * 
* * * * * * * * * * * * * * 
163 46.4 141 53.0 139 53.0 120 60.6 124 57.8 100 70.7 * * 
138 25.5 * * * * * * * * * * * * 
* * 108 48.8 107 48.4 114 44.7 * * 107 46.1 * * 
* * 92 63.5 * * 100 56.6 89 62.6 97 56.6 * * 
* * * * * * * * * * * * * * 
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* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 198 19.0 * * * * * * * * 
* * * * * * * * * * * * * * 
* * 119 51.9 * * * * 140 42.8 158 36.8 * * 
245 25.6 * * * * * * * * * * * * 
163 28.0 * * * * * * * * 150 27.8 * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
159 31.1 153 31.7 * * 162 28.8 168 27.2 171 26.2 * * 
* * 148 42.4 158 39.1 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
213 26.7 276 20.3 429 12.8 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * 122 57.8 * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * 111 67.8 * * * * * * * * * * 
* * * * * * 193 58.7 175 63.9 193 57.2 * * 
111 44.3 122 39.6 * * * * * * * * * * 
160 42.4 * * * * * * * * * * * * 
88 65.4 83 68.2 85 65.6 * * 103 52.4 * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
113 60.0 * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
121 64.8 * * 102 74.9 114 66.1 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
97 60.1 92 62.3 * * * * 103 52.8 * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
96 59.9 101 56.0 98 56.7 94 58.1 96 55.9 * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
142 56.5 159 49.8 155 50.3 177 43.4 * * * * * * 
88 73.4 97 65.7 107 58.7 99 62.6 104 58.7 * * * * 
101 60.3 * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
90 62.1 99 55.6 93 58.4 94 56.9 * * * * * * 
* * * * * * * * * * * * * * 
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SR fixation time interval specific sCr (umol/L) and CrC (ml/min) levels 
 
48 months 60 months 72 months 84 
months 
96 
months 
108 
months 
120 
months 
sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC sCr CrC 
* * * * * * * * * * * * * * 
* * * * * * * * * * 89 50 * * 
* * * * * * * * * * * * * * 
* * * * * * 88 79.3 96 71.6 * * * * 
* * * * 160 34.9 169 27.6 190 24.1 * * * * 
95 55.4 * * * * 94 52.2 94 52.3 * * * * 
* * * * * * * * * * * * * * 
* * * * * * 70 86.1 * * * * * * 
* * * * * * * * * * * * * * 
124 41.6 120 42.3 132 37.7 119 41.1 106 45.2 * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 102 43 * * * * * * * * 
* * * * * * 90 56.6 * * * * * * 
* * * * * * * * * * * * * * 
126 58.1 135 53.3 135 52.4 158 44.0 155 44.0 * * * * 
* * * * * * * * * * * * * * 
105 55.5 * * * * 106 56.8 * * * * * * 
* * * * * * * * * * * * * * 
* * * * 116 51.9 114 52.8 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 121 47.9 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
105 57.3 100 62.4 102 59 156 36.9 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
130 47.5 * * 160 37.3 194 30.3 * * * * * * 
* * * * * * * * * * * * * * 
* * 106 56.8 * * * * * * * * * * 
165 41.0 * * * * * * * * * * * * 
* * * * 102 43 105 42.0 * * * * * * 
* * * * * * * * * * * * * * 
142 60.8 * * * * 138 60.0 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 161 58.8 182 51.3 176 52.3 213 42.6 * * 
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* * * * * * 128 54.1 * * * * * * 
* * * * * * * * * * * * * * 
* * 113 59.6 * * 106 61.6 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * 125 36.2 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
164 29.1 168 27.9 157 29.4 171 26.5 * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
116 47.4 111 48.7 107 49.8 98 53.4 * * * * * * 
107 57.9 * * 133 45.0 148 39.1 * * * * * * 
91 80.0 95 75.6 83 85.3 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * 105 53.0 * * * * * * 
* * 112 77.4 108 79.2 * * * * * * * * 
123 48.1 161 36.1 * * * * * * * * * * 
70 100 80 86.9 81 84.6 * * * * * * * * 
109 44.6 96 49.8 100 47 * * * * * * * * 
* * * * * * * * * * * * * * 
101 62.5 106 58.5 92 66.3 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * 92 59.1 88 60.7 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * 80 63.7 * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * 100 62.4 * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
109 54.8 108 54.5 * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
131 45.1 * * 146 39.2 * * * * * * * * 
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* * 90 73.2 * * * * * * * * * * 
88 79.0 105 65.3 * * * * * * * * * * 
84 79.0 76 86.0 * * * * * * * * * * 
* * * * * * * * * * * * * * 
* * * * * * * * * * * * * * 
120 56.7 118 56.9 * * * * * * * * * * 
107 51.7 * * * * * * * * * * * * 
92 56.9 106 48.5 * * * * * * * * * * 
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Appendix I: Study 2 RAW data 
 
 
 
 
 
 
 
 
 
 
 
Group specific sCr (umol/L) and corresponding CC (mg/L) levels 
 
EVAR group 
 
OPEN group 
sCr CC sCr CC 
90 0.95 134 1.45 
114 1.00 159 1.60 
115 1.01 124 1.20 
139 1.10 112 1.07 
176 1.50 107 1.05 
91 0.90 89 0.88 
97 0.98 138 1.35 
86 0.89 106 1.02 
133 1.20 83 0.83 
127 1.22 147 1.44 
122 1.16 128 1.33 
101 1.02 114 1.14 
103 1.00 91 0.94 
114 1.11 88 0.82 
108 1.07 88 0.84 
88 0.85 99 1.00 
103 1.07 110 1.05 
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Appendix J: Study 3 RAW data 
 
 
 
 
 
 
EVAR group 
sCr (μmol/L) and corresponding NGAL levels (ng/ml) at specific time points 
Pre-operative 
 
4 hours post-op 24 hours post-op 48 hours post-op 6 weeks post-op 
sCr 
 
NGAL sCr NGAL sCr NGAL sCr NGAL sCr NGAL 
120 132 116 136 122 157 145 * 157 * 
81 116 85 97 88 148 96 122 94 231 
101 138 99 73 88 121 99 95 103 67 
86 199 86 104 93 210 134 146 * * 
93 88 90 146 94 130 101 123 99 107 
72 112 65 121 72 137 76 213 * * 
138 136 120 178 121 180 145 232 134 178 
154 * 140 74 137 184 152 164 160 137 
85 * 82 245 80 133 89 268 101 * 
95 82 88 101 90 81 88 49 97 90 
127 129 108 204 116 * 115 216 138 239 
123 124 130 149 107 67 102 206 133 128 
138 149 118 140 163 * 152 * 145 * 
121 143 103 136 126 77 154 179 * * 
101 53 85 * 95 102 97 132 100 137 
106 101 99 91 102 77 113 * 95 167 
104 102 78 154 95 103 117 173 98 * 
101 73 88 179 90 193 87 170 100 168 
84 110 79 115 78 96 * * 79 312 
86 144 77 155 94 319 88 262 102 322 
142 339 128 * 141 167 146 249 * * 
150 248 152 182 157 313 168 221 181 163 
121 172 107 189 131 195 116 323 129 * 
152 
 
 
 
 
 
 
 
 
 
OPEN group 
sCr (μmol/L) and corresponding NGAL levels (ng/ml) at specific time points 
Pre-operative 
 
4 hours post-op 24 hours post-op 48 hours post-op 6 weeks post-op 
sCr 
 
NGAL sCr NGAL sCr NGAL sCr NGAL sCr NGAL 
138 403 129 252 122 164 118 232 132 * 
108 264 96 160 88 * 87 300 * * 
156 149 148 190 135 216 172 165 164 * 
104 107 95 196 104 141 88 92 * * 
58 217 59 288 63 186 52 227 * * 
126 264 134 175 188 1051 217 318 119 * 
115 99 96 105 87 169 108 160 98 * 
114 112 95 130 109 409 109 172 * * 
94 110 108 293 102 137 84 146 91 64 
144 150 207 942 282 1335 512 98 160 123 
95 79 120 180 167 66 176 396 107 166 
211 106 191 * 192 308 227 186 199 140 
81 70 88 137 90 205 99 167 110 173 
69 194 78 251 80 168 76 230 72 * 
78 154 63 185 59 103 65 137 62 * 
71 218 95 530 101 212 73 132 72 164 
111 210 143 755 265 178 371 137 328 * 
129 172 124 299 141 137 130 179 138 140 
75 719 78 181 73 166 71 256 76 119 
96 104 121 149 114 192 105 125 83 152 
94 61 109 172 116 890 102 285 87 * 
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